CA2538413A1 - 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders - Google Patents
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders Download PDFInfo
- Publication number
- CA2538413A1 CA2538413A1 CA002538413A CA2538413A CA2538413A1 CA 2538413 A1 CA2538413 A1 CA 2538413A1 CA 002538413 A CA002538413 A CA 002538413A CA 2538413 A CA2538413 A CA 2538413A CA 2538413 A1 CA2538413 A1 CA 2538413A1
- Authority
- CA
- Canada
- Prior art keywords
- c8alkyl
- c8alkoxy
- och3
- hydroxy
- c8alkoxyc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1C(*)=C(*)C(N(*)c2nc(Nc3cc(*)c(*)c(*)c3)nc(*)c2*)=C*1 Chemical compound *C1C(*)=C(*)C(N(*)c2nc(Nc3cc(*)c(*)c(*)c3)nc(*)c2*)=C*1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
There is provided a method of preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity with compounds of formula (I) wherein X, R1, R2 , R3 , R4 , R5, R6, R7,R8 and R9 are as indicated in claim 1.
Description
2,4-DI(PHENYLAMINO)PYRIMIDINES USEFUL IN THE TREATMENT OF PROLIFERATIVE
DISORDERS
Use of Pyrimidine Derivatives The present invention relates the use of pyrimidine derivatives for the treatment of proliferative disorders, such as cancer, and to pharmaceutical compositions comprising them for the treatment of such proliferative disorders.
More particularly the present invention is based on the discovery that certain pyrimidine derivatives possess valuable, pharmacologically useful properties. In particular the pyrimidine derivatives used according to the present invention exhibit specific inhibitory activities that are of pharmacological interest. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK
.. This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK
ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK). The pyrimidine derivatives are useful for the inhibition of all such ALK-containing gene fusions.
The compounds that are useful as inhibitors of ALK or a gene fusion containing ALK are especially compounds of formula I
R~ i Rs / N / R$
2 ~ ~ ~ ~ ~ ~ 9 (I) R ~ _ Ra N H R
wherein X is =CR°- or =N-;
each of R°, R~, R2, R3 and R4 independently is hydrogen; hydroxy; C~-CBalkyl; CZ-CBalkenyl;
C3-Cscycloalkyl; C3-C$cycloalkyl-C1-Caalkyl; hydroxyC,-CBalkyl; C~-C$alkoxyC~-Csalkyl;
hydroxyC,-C$alkoxyC~-C$alkyl; arylC~-C$alkyl which optionally may be substituted on the ring by hydroxy, C~-Caalkoxy, carboxy or C1-CBalkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R', R2 and R3, independently, is halogen; halo-C,-Csalkyl; C~-C~alkoxy; halo-C~-CBalkoxy; hydroxyC~-C8alkoxy; C,-CaalkoxyC~-CBalkoxy; aryl; arylC~-CBalkoxy;
heteroaryl; heteroaryl-C~-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-CBalkoxycarbonyl; C2-CBalkylcarbonyl; -N(C~-CSalkyl)C(O) C~-CBalkyl; -N(R'°)R"
-CON(R'°)R"; -SO2N(R'°)R"; or -C~-C4-alkylene-S02N(R~°)R~'; wherein each of R'° and R" independently is hydrogen; hydroxy; C~-Caalkyl; C~-G$alkenyl; C3-CBcycloalkyl;
C3-CBcycloalkyl-C~-Csalkyl; C~-CsalkoxyC~-C8alkyl; hydroxyC~-C$alkoxyCl-CBalkyl;
hydroxyC,-CBalkyl; (C~-C$alkyl)-carbonyl; arylC~-Cgalkyl which optionally may be substituted on the ring by hydroxy, C~-C$alkoxy, carboxy or CZ-Csalkoxycarbonyl; or 5 to membered heterocyclic ring;
or R' and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C~-CBalkyl; halo-C~-CBalkyl;
CZ-Csalkenyl; C2-C$alkynyl; C3-C$cycloalkyl; C3-CacycloalkylC~-CBalkyl; C5-C~°arylC~-CBalkyl;
each of R', R$ and R9 is independently hydrogen; hydroxy; C~-CBalkyl; C2-Csalkenyl;
halo-C~-C$alkyl; C~-C$alkoxy; C3-CBcycloalkyl; C3-C$cycloaIkyIC~-Csalkyl;
arylC~-C8alkyl;
-Y-R'Z wherein Y is a direct bond or,O and R'2 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxjr; (C,-C$alkoxy)-carbonyl; -N(C,.salkyl)-CO-NR'°R"; -CONK'°R'~; -N(R'°)(R");
-S02N(R'°)R"; or R' and Ra or R$ and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form.
DISORDERS
Use of Pyrimidine Derivatives The present invention relates the use of pyrimidine derivatives for the treatment of proliferative disorders, such as cancer, and to pharmaceutical compositions comprising them for the treatment of such proliferative disorders.
More particularly the present invention is based on the discovery that certain pyrimidine derivatives possess valuable, pharmacologically useful properties. In particular the pyrimidine derivatives used according to the present invention exhibit specific inhibitory activities that are of pharmacological interest. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK
.. This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK
ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK). The pyrimidine derivatives are useful for the inhibition of all such ALK-containing gene fusions.
The compounds that are useful as inhibitors of ALK or a gene fusion containing ALK are especially compounds of formula I
R~ i Rs / N / R$
2 ~ ~ ~ ~ ~ ~ 9 (I) R ~ _ Ra N H R
wherein X is =CR°- or =N-;
each of R°, R~, R2, R3 and R4 independently is hydrogen; hydroxy; C~-CBalkyl; CZ-CBalkenyl;
C3-Cscycloalkyl; C3-C$cycloalkyl-C1-Caalkyl; hydroxyC,-CBalkyl; C~-C$alkoxyC~-Csalkyl;
hydroxyC,-C$alkoxyC~-C$alkyl; arylC~-C$alkyl which optionally may be substituted on the ring by hydroxy, C~-Caalkoxy, carboxy or C1-CBalkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R', R2 and R3, independently, is halogen; halo-C,-Csalkyl; C~-C~alkoxy; halo-C~-CBalkoxy; hydroxyC~-C8alkoxy; C,-CaalkoxyC~-CBalkoxy; aryl; arylC~-CBalkoxy;
heteroaryl; heteroaryl-C~-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-CBalkoxycarbonyl; C2-CBalkylcarbonyl; -N(C~-CSalkyl)C(O) C~-CBalkyl; -N(R'°)R"
-CON(R'°)R"; -SO2N(R'°)R"; or -C~-C4-alkylene-S02N(R~°)R~'; wherein each of R'° and R" independently is hydrogen; hydroxy; C~-Caalkyl; C~-G$alkenyl; C3-CBcycloalkyl;
C3-CBcycloalkyl-C~-Csalkyl; C~-CsalkoxyC~-C8alkyl; hydroxyC~-C$alkoxyCl-CBalkyl;
hydroxyC,-CBalkyl; (C~-C$alkyl)-carbonyl; arylC~-Cgalkyl which optionally may be substituted on the ring by hydroxy, C~-C$alkoxy, carboxy or CZ-Csalkoxycarbonyl; or 5 to membered heterocyclic ring;
or R' and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C~-CBalkyl; halo-C~-CBalkyl;
CZ-Csalkenyl; C2-C$alkynyl; C3-C$cycloalkyl; C3-CacycloalkylC~-CBalkyl; C5-C~°arylC~-CBalkyl;
each of R', R$ and R9 is independently hydrogen; hydroxy; C~-CBalkyl; C2-Csalkenyl;
halo-C~-C$alkyl; C~-C$alkoxy; C3-CBcycloalkyl; C3-C$cycloaIkyIC~-Csalkyl;
arylC~-C8alkyl;
-Y-R'Z wherein Y is a direct bond or,O and R'2 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxjr; (C,-C$alkoxy)-carbonyl; -N(C,.salkyl)-CO-NR'°R"; -CONK'°R'~; -N(R'°)(R");
-S02N(R'°)R"; or R' and Ra or R$ and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form.
Any aryl may be phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl, preferably phenyl.
Heteroaryl is an aromatic heterocyclic ring, e.g. a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring.
Any heterocyclic ring may be saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.
Examples of heterocyclic rings or heteroaryl include e.g. morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, purinyl, pyrimidinyl, N-methyl-aza-cycloheptan-4-yl, indolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, benzothiazolyl, thiazolyl, imidazolyl, benzimidazolyl, benzoxadiazolyl, benzotriazolyl, indanyl, oxadiazolyl, pyrazolyl, triazolyl, and tetrazolyl. Preferred heterocyclic rings or heteroaryl are morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, N-methyl-aza-cycloheptan-4-yl, thiazolyl, imidazolyl and tetrazolyl.
When R' and R$ or R$ and R9 form together with the carbon atoms to which they are attached a 5 or 6 membered carbocyclic ring, this may preferably be cyclopentyl or cyclohexyl.
Halo-alkyl is alkyl wherein one or more H are replaced by halogen, e.g. CF3.
Any alkyl or alkyl moiety may be linear or branched. C~_8alkyl is preferably C~~alkyl. C~_ $alkoxy is preferably C~.~alkoxy. Any alkyl, alkoxy, alkenyl, cycloalkyl, heterocyclic ring, aryl or heteroaryl may be; unless otherwise stated, unsubstituted or substituted by one or more substituents selected from halogen; OH; C~-C8alkyl; C,-Csalkoxy; nitro; cyano;
COON;
carbamoyl; C(NH2)=NOH; -N(R'°)R"; C3-Cscycloalkyl; 3 to 7 membered heterocyclic ring;
phenyl; phenyl-C~~alkyl; 5 or 6 membered heteroaryl. When alkyl, alkoxy or alkenyl is substituted, the substituent is preferably on the terminal C atom. When the heterocyclic ring or heteroaryl is substituted, e.g. as disclosed above, this may be on one or more ring carbon atoms andlor ring nitrogen atom when present. Examples of a substituent on a ring nitrogen atom are e.g.
C,_salkyl, carbamoyl, -C(NH2)=NOH, -NR'°R", C~cycloalkyl or phenyl-C~.~alkyl, preferably C~_8alkyl, C3~cycloalkyl or phenyl-C~~alkyl.
Heteroaryl is an aromatic heterocyclic ring, e.g. a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring.
Any heterocyclic ring may be saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.
Examples of heterocyclic rings or heteroaryl include e.g. morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, purinyl, pyrimidinyl, N-methyl-aza-cycloheptan-4-yl, indolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, benzothiazolyl, thiazolyl, imidazolyl, benzimidazolyl, benzoxadiazolyl, benzotriazolyl, indanyl, oxadiazolyl, pyrazolyl, triazolyl, and tetrazolyl. Preferred heterocyclic rings or heteroaryl are morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, N-methyl-aza-cycloheptan-4-yl, thiazolyl, imidazolyl and tetrazolyl.
When R' and R$ or R$ and R9 form together with the carbon atoms to which they are attached a 5 or 6 membered carbocyclic ring, this may preferably be cyclopentyl or cyclohexyl.
Halo-alkyl is alkyl wherein one or more H are replaced by halogen, e.g. CF3.
Any alkyl or alkyl moiety may be linear or branched. C~_8alkyl is preferably C~~alkyl. C~_ $alkoxy is preferably C~.~alkoxy. Any alkyl, alkoxy, alkenyl, cycloalkyl, heterocyclic ring, aryl or heteroaryl may be; unless otherwise stated, unsubstituted or substituted by one or more substituents selected from halogen; OH; C~-C8alkyl; C,-Csalkoxy; nitro; cyano;
COON;
carbamoyl; C(NH2)=NOH; -N(R'°)R"; C3-Cscycloalkyl; 3 to 7 membered heterocyclic ring;
phenyl; phenyl-C~~alkyl; 5 or 6 membered heteroaryl. When alkyl, alkoxy or alkenyl is substituted, the substituent is preferably on the terminal C atom. When the heterocyclic ring or heteroaryl is substituted, e.g. as disclosed above, this may be on one or more ring carbon atoms andlor ring nitrogen atom when present. Examples of a substituent on a ring nitrogen atom are e.g.
C,_salkyl, carbamoyl, -C(NH2)=NOH, -NR'°R", C~cycloalkyl or phenyl-C~.~alkyl, preferably C~_8alkyl, C3~cycloalkyl or phenyl-C~~alkyl.
Preferably substituted alkyl or alkoxy as R7 is alkyl or alkoxy substituted on the terminal C
atom by OH, C~~alkoxy or a heterocyclic ring. When R~° or R'1 is a 5 to 10 membered heterocyclic ring, it may be e.g. thiazolyl.
Halogen may be F, CI, Br, or I
Preferably at most one of R', RZ or R3 is CONK'°R" or S02NR'°R", more preferably SO2NR'°R".
The compounds of the invention may exist in free form or in salt form, e.g.
addition salts with e.g. organic or inorganic acids, for example trifluoroacetic acid or hydrochloride acid, or salts obtainable when they comprise a carboxy group, e.g. with a base, for example alkali salts such as sodium, potassium, or substituted or unsubstituted ammonium salts.
In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:
(a) X is =CR°;
(b) R° is hydrogen; halogen, e.g. CI; C~-C4alkyl, e.g. methyl or ethyl;
C~~alkoxy, e.g. methoxy;
preferably hydrogen;
(c) R' is hydrogen; halogen, e.g. CI or F; OH; C~-CBalkyl, e.g. methyl or ethyl; substituted C~_8alkyl, e.g. terminally OH substituted C~_$alkyl; -SO2N(R'°)R"; -N(C~.~alkyl)C(O) C~_ 4alkyl; a 5 or 6 membered heterocyclic ring optionally substituted on a ring N
atom (when possible); C~-C$alkoxy, e.g. methoxy; aryl, e.g. phenyl; or form together with R2 and the C-atoms to which R~ and RZ are attached 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;
(d) Rz is hydrogen; hydroxy; C~-CBalkyl, e.g. methyl or ethyl; substituted C~$alkyl, e.g.
terminally OH- or C~~-alkoxy substituted C~$alkyl; C~_$alkoxy; C,-C4alkoxyC~-C8alkoxy; -CON(R'°)R", -S02N(R'°)R"; or forms together with R' and the C-atoms to which R' and R2 are attached a 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;
(e) R3 is hydrogen; halogen, e.g. CI, Br; hydroxy; C~-CBalkyl, e.g. methyl or ethyl; substituted Ci_salkyl, e.g. terminally OH substituted C~~alkyf; carboxy; CONK'°R"; -S02N(R'°)R"; a or 6 membered heterocyclic ring optionally substituted on a ring nitrogen atom (when possible); or forms together with R4 and the N and C atoms to which R3 and R~
are attached a 6 membered heterocyclic ring;
atom by OH, C~~alkoxy or a heterocyclic ring. When R~° or R'1 is a 5 to 10 membered heterocyclic ring, it may be e.g. thiazolyl.
Halogen may be F, CI, Br, or I
Preferably at most one of R', RZ or R3 is CONK'°R" or S02NR'°R", more preferably SO2NR'°R".
The compounds of the invention may exist in free form or in salt form, e.g.
addition salts with e.g. organic or inorganic acids, for example trifluoroacetic acid or hydrochloride acid, or salts obtainable when they comprise a carboxy group, e.g. with a base, for example alkali salts such as sodium, potassium, or substituted or unsubstituted ammonium salts.
In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:
(a) X is =CR°;
(b) R° is hydrogen; halogen, e.g. CI; C~-C4alkyl, e.g. methyl or ethyl;
C~~alkoxy, e.g. methoxy;
preferably hydrogen;
(c) R' is hydrogen; halogen, e.g. CI or F; OH; C~-CBalkyl, e.g. methyl or ethyl; substituted C~_8alkyl, e.g. terminally OH substituted C~_$alkyl; -SO2N(R'°)R"; -N(C~.~alkyl)C(O) C~_ 4alkyl; a 5 or 6 membered heterocyclic ring optionally substituted on a ring N
atom (when possible); C~-C$alkoxy, e.g. methoxy; aryl, e.g. phenyl; or form together with R2 and the C-atoms to which R~ and RZ are attached 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;
(d) Rz is hydrogen; hydroxy; C~-CBalkyl, e.g. methyl or ethyl; substituted C~$alkyl, e.g.
terminally OH- or C~~-alkoxy substituted C~$alkyl; C~_$alkoxy; C,-C4alkoxyC~-C8alkoxy; -CON(R'°)R", -S02N(R'°)R"; or forms together with R' and the C-atoms to which R' and R2 are attached a 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;
(e) R3 is hydrogen; halogen, e.g. CI, Br; hydroxy; C~-CBalkyl, e.g. methyl or ethyl; substituted Ci_salkyl, e.g. terminally OH substituted C~~alkyf; carboxy; CONK'°R"; -S02N(R'°)R"; a or 6 membered heterocyclic ring optionally substituted on a ring nitrogen atom (when possible); or forms together with R4 and the N and C atoms to which R3 and R~
are attached a 6 membered heterocyclic ring;
(f) R4 is hydrogen; or forms together with R3 and the N and C atoms to which R3 and R4 are attached a 6 membered heterocyclic ring; preferably hydrogen;
(g) R5 is hydrogen; halogen; C~~alkyl; or CFs;
(h) R6 is hydrogen;
(i) R' is hydrogen; hydroxy; C~~alkyl; substituted C~~alkyl, e.g. terminally OH substituted C~~alkyl; C~.~alkoxy; substituted C~_8alkoxy, e.g. terminally substituted by OH, C,~alkoxy or a heterocjrclic ring; NR'°R"; -S02N(R'°)R"; -Y-R'~; CF3; or R'forms together with R$
and the C-atoms to which R' and R8 are attached a 5 membered heteroaryl residue, e.g.
bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -NH-N=N- or -N=N-NH-;
(k) R$ is hydrogen; hydroxy; C,~alkoxy; carboxy; a 5 or 6 membered heterocyclic ring optionally substituted on a ring C or N atom; N(C~~alkyl)-CO- NR'°R";
or forms with R' or R9 and the C-atoms to which R' and R8 or R8 and R9 , respectively, are attached a 5 membered heteroaryl residue, e.g. bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH--CH=N-NH-, -NH-N=N- or -N=N-NH-;
(I) R9 is hydrogen; C~~.alkoxy; NR'°R"; or forms with R$ and the C
atoms to which R$ and R9 are attached a 5 membered heteroaryl, e.g. bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -NH-N=N- or-N=N-NH-;
(m) one of R'° and R", independently, is hydrogen or C~.~alkyl and the other is hydrogen;
OH; C~_aalkyl, substituted C~~alkyl, e.g. terminally substituted by OH, C~cycloalkyl or a heterocyclic ring; Cz$alkenyl; C~Bcycloalkyl; hydroxyC~$alkoxyC~_$alleyl; or a membered heterocyclic ring.
R3 is preferably SO2NR'°R"
The invention also provides the use of a compound of formula I for the preparation of a medicament for the treatment of a hematological and neoplastic disease.
The present invention also provides a process for the production of a compound of formula I, comprising reacting a compound of formula II
(g) R5 is hydrogen; halogen; C~~alkyl; or CFs;
(h) R6 is hydrogen;
(i) R' is hydrogen; hydroxy; C~~alkyl; substituted C~~alkyl, e.g. terminally OH substituted C~~alkyl; C~.~alkoxy; substituted C~_8alkoxy, e.g. terminally substituted by OH, C,~alkoxy or a heterocjrclic ring; NR'°R"; -S02N(R'°)R"; -Y-R'~; CF3; or R'forms together with R$
and the C-atoms to which R' and R8 are attached a 5 membered heteroaryl residue, e.g.
bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -NH-N=N- or -N=N-NH-;
(k) R$ is hydrogen; hydroxy; C,~alkoxy; carboxy; a 5 or 6 membered heterocyclic ring optionally substituted on a ring C or N atom; N(C~~alkyl)-CO- NR'°R";
or forms with R' or R9 and the C-atoms to which R' and R8 or R8 and R9 , respectively, are attached a 5 membered heteroaryl residue, e.g. bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH--CH=N-NH-, -NH-N=N- or -N=N-NH-;
(I) R9 is hydrogen; C~~.alkoxy; NR'°R"; or forms with R$ and the C
atoms to which R$ and R9 are attached a 5 membered heteroaryl, e.g. bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -NH-N=N- or-N=N-NH-;
(m) one of R'° and R", independently, is hydrogen or C~.~alkyl and the other is hydrogen;
OH; C~_aalkyl, substituted C~~alkyl, e.g. terminally substituted by OH, C~cycloalkyl or a heterocyclic ring; Cz$alkenyl; C~Bcycloalkyl; hydroxyC~$alkoxyC~_$alleyl; or a membered heterocyclic ring.
R3 is preferably SO2NR'°R"
The invention also provides the use of a compound of formula I for the preparation of a medicament for the treatment of a hematological and neoplastic disease.
The present invention also provides a process for the production of a compound of formula I, comprising reacting a compound of formula II
R~ X R5 /
w R2 \ N N Y (II) R3 R~
wherein R', R~, R3, R4, R5, Rs and X are as defined above, and Y is a leaving group, preferably halogen such as bromide, iodine, or in particular chloride;
with a compound of formula III
R' R$
H N / 9 (III) R
wherein R', R$ and R9 are as defined above;
and recovering the resulting compound of formula I in free or in form of a salt, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.
The process may be performed according to methods known in the art, e.g. as described in examples 1 to 4.
The compound of formula II used as starting materials may be obtained by reacting a compound of formula IV
/ ~N
(IV) Y N Y
with a compound of formula V
R~ X
R2 / NHR4 (V) wherein R', RZ, R3, R4, R5, R6, Y and X are as defined above.
_7_ The compounds of formula IV and V are known or may be produced in accordance with known procedures.
The following examples illustrate the invention without any limitation.
The following abbreviations are employed: APC = allophycocyanine, BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, cDNA = complementary DNA, DCM =
dichloromethane, DIAD = diisopropyl azodicarboxylate, DMAP = 4-dimethylaminopyridine, DMF = dimethylformamide, DMSO = dimethylsulfoxide, DMF = dimethylformamide;
Pmc =
2,2,5,7,8-pentamethylchroman; tBu = tert.-butyl; DIPCDI = N,N'-diisopropylcarbodiimid; DTT
= 1,4-dithio-D,L-treitol, DNA = deoxyribonucleic acid, EDTA =
ethylenediaminetetra-acetic acid, Lck = lymphoid T-cell protein tyrosine kinase, LAT-11 = linker for activation of T cell , RT = room temperature; RT-PCR = reverse transcription polymerase chain reaction, MS =
molecular ion (e.g. M+H'+) determined by electrospray mass spectroscopy; Eu =
europium.
_$_ Example 1: 2-[2-(1 H-Indazol-6-ylamino)-pyrimidin-4-ylamino)-benzenesulfonamide H H
N~N \ N
, /N ~ / ~N
NH
/ s0 ~S~NH~
(a) 2-(2-Chloro pyrimidin-4 ylamino)-benzenesulfonamide: To a suspension of 8.52 g (49.47 mmol) 2-aminobenzenesulfonamide in 200 ml isopropanol is added 22.1 g (148.42 mmol, 3 equivalent) 2,4-dichloropyrimidine and 20 ml 10 M
hydrochloric acid (200 mmol, 4 equivalent). The suspension is stirred at 60°C for 2 h 15 min.
The reaction mixture is dilluted with 2 I ethyl acetate and 500 ml water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is reextracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate is formed and removed by filtration (side product). The filtrate is evaporated to 100 ml whereupon the product crystallizes to give 2-(2-chloro-pyrimidin-4.-ylamino)-benzenesulfonamide (97% purity by HPLC). The mother liquor of this cristallisation is furfiher purified by column chromatography and crystallisation to give further 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide.
(b) 2-(2-(7H-Indazol-6-ylamino) pyrimidin-4 ylaminoJ-benzenesulfonamide: To a suspension of 7.25 g (25.46 mmol) 2-(2-Chloro-pyrimidin-4-ylamino)-benzenesulfonamide and 4.07 g (30.55 mmol, 1.2 equivalent) 6-aminoindazole in 400 ml isopropanol is added 13 ml conc.
HCI* (130 mmol, 5 equivalent). The suspension is refluxed for 4 h 30 min. The reaction mixture is dilluted with 1.5 I ethyl acetate and 1 I water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is re-extracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate (1.01 g) is formed and removed by filtration (side product). The filtrate is purified by chromatography on 200 g silica gel eluting with ethyl acetate/methanol 9515 v/v. Upon evaporation crystalls are formed which are filtered to give the title compound.
' H NMR (400 MHz, DMSO-ds): a 9.42 (s, 1 H), 8.34 (d, 1 h), 8.28 (d, 1 H), 8.27 (s, 1 H), 7.93 (s, 1 H, 7.88 (d, 1 H), 7.62 (m, 2H), 7.32 (d, 1 H), 7.24 (t, 1 H), 6.40 (d, 1 H).
MS m/z (%): 382 (M+H, 100);
-Example 2: 2-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-ylamino~-benzenesulfonamide H
N\ /N ~ O~
' , NN I / Oi NH Ow / ~O
oS~NHz The title compound is prepared from 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide as described in Example 1 using 3,4,5-Trimethoxy-phenylamine instead of 6-aminoindazole in step (b).
'H NMR (400 MHz, DMSO-ds): ~ 9.18 (s, 1 H), 8.22 (d, 1 H), 8.17 (d, 1 H), 7.89 (d, 1 H), 7.55 (t, 1 H), 7.25 (t, 1 H), 7.14 (s, 2H), 6.40 (d, 1 H), 3.69 (s, 6H), 3.62 (s, 3H). MS m/z (%): 432 (M+H, 100);
Example 3: 2-methyl-6-[2-(3,4,5-Trimethoxy-phenytamino)-pyrimidin-4-ylamino]-benzenesulfonamide H
N1 /N ~ O~
NN I / O i NH O~
/ ~O
OS.NHa The tilte compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methyl-benzenesulfonamide is used instead of 2-aminobenzenesulfonamide.
2 Amino-6-methyl-benzenesulfonamide may be prepared as described by Girard, Y
el aL; J.
J. Chem. Soc. Perkin Trans. I X979, 4, 7043-7047.' Under an atmosphere of nitrogen m-toluidin (32.1 g, 32.5 ml, 0.30 mmol) is added dropwise to a solution of chlorosulfonyl isocyanate (51.3 ml, 83.6 g, 0.59 mmol) in nitroethane (400 ml) at -55 -49°C. The cold bath is removed and the mixture allowed to warm to -8°C, whereupon aluminium chloride (51 g, 0.38 mmol) is added. Heating the mixture to 100°C for 20 min forms a clear brown solution, which is cooled to RT and poured on ice. After filtration, washing with ice water and diethyl ether the precipitate is collected and dissolved in dioxane (300 ml). Water (1000 ml) and conc. HC1 (1500 ml) are added to form a suspension, which is heated to 120°C for 18h. After cooling to RT the clear brown solution is washed with diethyl etherihexane (1400 ml, 1l1 viv) and adjusted to pH = 8 by addition of sodium carbonate. Extraction using ethyl acetate (2 x 1000 ml), washing of the organic phase with water (500 ml) and brine (500 ml), drying (magnesium sulfate) and concentration yields a brown solid, which is purified by chromatography on silica using methylene chloride/ethanol (100/1 vlv) to yield the desired product as a white solid.
Melting point: 72-75°C (Propan-2-ol);
'H NMR (400 MHz, DMSO-d6): ~ 2.64 (s, 3H, Me), 3.63 (s, 3H, OMe), 3.68 (s, 6H, OMe), 6.31 (d, J = 5Hz, 1 H, pyrimidine CH), 7.07 (d, J = BHz, 1 H, arom. CH), 7.15 (s, 2H, arom.
CH), 7.40 (t, J = BHz, 1 H, arom. CH), 7.65 (s, 2H, SO2NH2), 8.04 (d, J = 8Hz, 1 H, arom. CH), 8.12 (d, J = 5Hz, 1 H, pyrimidine CH), 9.14 (s, 1 H, NH), 9.40 (s, 1 H, NH).
MS (ES+) m/z: 446 (MH+), 468 (MNa+) MS (ES'): 444 (M-H)' Example 4: 2-Methoxy-6-(2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino~-benzenesulfonamide H
N\ /N ~ O~
iN I / Oi NH O~
/ ~O
O oS~NH2 The title compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methoxy-benzenesulfonamide is used instead of 2-Amino-6-methyl-benzenesulfonamide.
2 Amino-6-methoxy benzenesulfonamide may be prepared from 12.3 g of meta-anisidine following an analogous procedure as described in Example 1a. NMR (400 MHz, DMSO-ds):
X3.62 (s, 3H, OMe), 3.69 (s, 6H, OMe), 3.91 (s, 3H, OMe), 6.31 (d, J = 5Hz, 1 H, pyrimidine CH), 6.86 (d, J = 8Hz, 1 H, arom. CH), 7.12 (s, 2H, arom. CH), 7.43 (t, J =
8Hz, 1 H, arom.
CH), 8.01 (d, J = BHz, 1 H, arum. CH), 8.11 (d, J = 5Hz, 1 H, pyrimidine CH), 9.18 (s, 1 H, NH), 9.79 (br, 1 H, NH).
MS (ES+): 462.2 (MH+), 484.2 (MNa+) MS (ES'): 460.3 (M-H)' The compounds of formula X~
R~
i ~ ~ ~I i N N- 'N
R
wherein R3, R' and R8 are as defined in Table 1, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R' R' R MS
Data *ES+ *ES- *EI
-OH -O-(1-methyl)-azacyclohept--H 406 404 6 -S02NH2 -O-(1-methyl)-azacyclohept--H 469.3 7 -S02NH2 -O-2-(1-methyl-azacyclopent--H 469.3 2- I -eth I
w R2 \ N N Y (II) R3 R~
wherein R', R~, R3, R4, R5, Rs and X are as defined above, and Y is a leaving group, preferably halogen such as bromide, iodine, or in particular chloride;
with a compound of formula III
R' R$
H N / 9 (III) R
wherein R', R$ and R9 are as defined above;
and recovering the resulting compound of formula I in free or in form of a salt, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.
The process may be performed according to methods known in the art, e.g. as described in examples 1 to 4.
The compound of formula II used as starting materials may be obtained by reacting a compound of formula IV
/ ~N
(IV) Y N Y
with a compound of formula V
R~ X
R2 / NHR4 (V) wherein R', RZ, R3, R4, R5, R6, Y and X are as defined above.
_7_ The compounds of formula IV and V are known or may be produced in accordance with known procedures.
The following examples illustrate the invention without any limitation.
The following abbreviations are employed: APC = allophycocyanine, BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, cDNA = complementary DNA, DCM =
dichloromethane, DIAD = diisopropyl azodicarboxylate, DMAP = 4-dimethylaminopyridine, DMF = dimethylformamide, DMSO = dimethylsulfoxide, DMF = dimethylformamide;
Pmc =
2,2,5,7,8-pentamethylchroman; tBu = tert.-butyl; DIPCDI = N,N'-diisopropylcarbodiimid; DTT
= 1,4-dithio-D,L-treitol, DNA = deoxyribonucleic acid, EDTA =
ethylenediaminetetra-acetic acid, Lck = lymphoid T-cell protein tyrosine kinase, LAT-11 = linker for activation of T cell , RT = room temperature; RT-PCR = reverse transcription polymerase chain reaction, MS =
molecular ion (e.g. M+H'+) determined by electrospray mass spectroscopy; Eu =
europium.
_$_ Example 1: 2-[2-(1 H-Indazol-6-ylamino)-pyrimidin-4-ylamino)-benzenesulfonamide H H
N~N \ N
, /N ~ / ~N
NH
/ s0 ~S~NH~
(a) 2-(2-Chloro pyrimidin-4 ylamino)-benzenesulfonamide: To a suspension of 8.52 g (49.47 mmol) 2-aminobenzenesulfonamide in 200 ml isopropanol is added 22.1 g (148.42 mmol, 3 equivalent) 2,4-dichloropyrimidine and 20 ml 10 M
hydrochloric acid (200 mmol, 4 equivalent). The suspension is stirred at 60°C for 2 h 15 min.
The reaction mixture is dilluted with 2 I ethyl acetate and 500 ml water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is reextracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate is formed and removed by filtration (side product). The filtrate is evaporated to 100 ml whereupon the product crystallizes to give 2-(2-chloro-pyrimidin-4.-ylamino)-benzenesulfonamide (97% purity by HPLC). The mother liquor of this cristallisation is furfiher purified by column chromatography and crystallisation to give further 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide.
(b) 2-(2-(7H-Indazol-6-ylamino) pyrimidin-4 ylaminoJ-benzenesulfonamide: To a suspension of 7.25 g (25.46 mmol) 2-(2-Chloro-pyrimidin-4-ylamino)-benzenesulfonamide and 4.07 g (30.55 mmol, 1.2 equivalent) 6-aminoindazole in 400 ml isopropanol is added 13 ml conc.
HCI* (130 mmol, 5 equivalent). The suspension is refluxed for 4 h 30 min. The reaction mixture is dilluted with 1.5 I ethyl acetate and 1 I water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is re-extracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate (1.01 g) is formed and removed by filtration (side product). The filtrate is purified by chromatography on 200 g silica gel eluting with ethyl acetate/methanol 9515 v/v. Upon evaporation crystalls are formed which are filtered to give the title compound.
' H NMR (400 MHz, DMSO-ds): a 9.42 (s, 1 H), 8.34 (d, 1 h), 8.28 (d, 1 H), 8.27 (s, 1 H), 7.93 (s, 1 H, 7.88 (d, 1 H), 7.62 (m, 2H), 7.32 (d, 1 H), 7.24 (t, 1 H), 6.40 (d, 1 H).
MS m/z (%): 382 (M+H, 100);
-Example 2: 2-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-ylamino~-benzenesulfonamide H
N\ /N ~ O~
' , NN I / Oi NH Ow / ~O
oS~NHz The title compound is prepared from 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide as described in Example 1 using 3,4,5-Trimethoxy-phenylamine instead of 6-aminoindazole in step (b).
'H NMR (400 MHz, DMSO-ds): ~ 9.18 (s, 1 H), 8.22 (d, 1 H), 8.17 (d, 1 H), 7.89 (d, 1 H), 7.55 (t, 1 H), 7.25 (t, 1 H), 7.14 (s, 2H), 6.40 (d, 1 H), 3.69 (s, 6H), 3.62 (s, 3H). MS m/z (%): 432 (M+H, 100);
Example 3: 2-methyl-6-[2-(3,4,5-Trimethoxy-phenytamino)-pyrimidin-4-ylamino]-benzenesulfonamide H
N1 /N ~ O~
NN I / O i NH O~
/ ~O
OS.NHa The tilte compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methyl-benzenesulfonamide is used instead of 2-aminobenzenesulfonamide.
2 Amino-6-methyl-benzenesulfonamide may be prepared as described by Girard, Y
el aL; J.
J. Chem. Soc. Perkin Trans. I X979, 4, 7043-7047.' Under an atmosphere of nitrogen m-toluidin (32.1 g, 32.5 ml, 0.30 mmol) is added dropwise to a solution of chlorosulfonyl isocyanate (51.3 ml, 83.6 g, 0.59 mmol) in nitroethane (400 ml) at -55 -49°C. The cold bath is removed and the mixture allowed to warm to -8°C, whereupon aluminium chloride (51 g, 0.38 mmol) is added. Heating the mixture to 100°C for 20 min forms a clear brown solution, which is cooled to RT and poured on ice. After filtration, washing with ice water and diethyl ether the precipitate is collected and dissolved in dioxane (300 ml). Water (1000 ml) and conc. HC1 (1500 ml) are added to form a suspension, which is heated to 120°C for 18h. After cooling to RT the clear brown solution is washed with diethyl etherihexane (1400 ml, 1l1 viv) and adjusted to pH = 8 by addition of sodium carbonate. Extraction using ethyl acetate (2 x 1000 ml), washing of the organic phase with water (500 ml) and brine (500 ml), drying (magnesium sulfate) and concentration yields a brown solid, which is purified by chromatography on silica using methylene chloride/ethanol (100/1 vlv) to yield the desired product as a white solid.
Melting point: 72-75°C (Propan-2-ol);
'H NMR (400 MHz, DMSO-d6): ~ 2.64 (s, 3H, Me), 3.63 (s, 3H, OMe), 3.68 (s, 6H, OMe), 6.31 (d, J = 5Hz, 1 H, pyrimidine CH), 7.07 (d, J = BHz, 1 H, arom. CH), 7.15 (s, 2H, arom.
CH), 7.40 (t, J = BHz, 1 H, arom. CH), 7.65 (s, 2H, SO2NH2), 8.04 (d, J = 8Hz, 1 H, arom. CH), 8.12 (d, J = 5Hz, 1 H, pyrimidine CH), 9.14 (s, 1 H, NH), 9.40 (s, 1 H, NH).
MS (ES+) m/z: 446 (MH+), 468 (MNa+) MS (ES'): 444 (M-H)' Example 4: 2-Methoxy-6-(2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino~-benzenesulfonamide H
N\ /N ~ O~
iN I / Oi NH O~
/ ~O
O oS~NH2 The title compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methoxy-benzenesulfonamide is used instead of 2-Amino-6-methyl-benzenesulfonamide.
2 Amino-6-methoxy benzenesulfonamide may be prepared from 12.3 g of meta-anisidine following an analogous procedure as described in Example 1a. NMR (400 MHz, DMSO-ds):
X3.62 (s, 3H, OMe), 3.69 (s, 6H, OMe), 3.91 (s, 3H, OMe), 6.31 (d, J = 5Hz, 1 H, pyrimidine CH), 6.86 (d, J = 8Hz, 1 H, arom. CH), 7.12 (s, 2H, arom. CH), 7.43 (t, J =
8Hz, 1 H, arom.
CH), 8.01 (d, J = BHz, 1 H, arum. CH), 8.11 (d, J = 5Hz, 1 H, pyrimidine CH), 9.18 (s, 1 H, NH), 9.79 (br, 1 H, NH).
MS (ES+): 462.2 (MH+), 484.2 (MNa+) MS (ES'): 460.3 (M-H)' The compounds of formula X~
R~
i ~ ~ ~I i N N- 'N
R
wherein R3, R' and R8 are as defined in Table 1, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R' R' R MS
Data *ES+ *ES- *EI
-OH -O-(1-methyl)-azacyclohept--H 406 404 6 -S02NH2 -O-(1-methyl)-azacyclohept--H 469.3 7 -S02NH2 -O-2-(1-methyl-azacyclopent--H 469.3 2- I -eth I
8 -OH -O-2-(1-pi arid I -eth-OCH3 436.3434.4 I
9 . -OH -O-2-(1-methyl-azacyclopent--H 406 404 2-I)-eth I
_ _ _ -SO2NH2 -O-CH2CH2CH~-1-imidazol-OCH3 496 494 11 -S02NH2 I -OCH~ 499.2497.3 -O-2- 1- i arid I -eth I
12 -SOzNH2 -O-CH2CHz-1-methyl- -H 4fi6 464 imidazoi-1- I
13 -OH -O-2-[1- 1,2,4-triazolyl)-H 390 388 -eth I
14 -OH -O-2-h drox eth I -OCH3 369.4367.3 -SO~NH2 -O-2-h dro eth I -OCH3 431 16 -SO~NH2 -O-CH2CH2-1-imidazol -OCH3 I
17 -S02NH2 -O-2- 1-(1,2,4-triazol-H 452 I -eth I
18 -S02NH~ -NH-N=N- 381 19 -SO2NHCH3 -O-CH2CHz-1-imidazol -OCH3 496 494 I
-S02NH2 -O-2-(1-pi arid I -eth-H 469 467 I
21 -S02NH2 -O-CH2CH2-1-imidazol -H 452 450 I
22 -OH -O-2- 1- iperid I)-eth-H 406 I
23 -COOH -4-mor holino -H
24 -OH -O-CH2CH~CH~-1-imidazol-OCH3 433 431 I
-S02NHCH3 -CH=N-NH- 396 394 26 -S02NH2 -O-2- 4-mor holino -H 471 469 eth 1 28 -OH -O-2- 4-mor holino -H 408 406 eth I
29 -SOZNH2 -CH=N-NH- 381 -S02NHCH3 -O-CH2CH2-1-imidazol I -H
31 -COON Amino -H 322 32 -SO2NH2 -O-CH~CH2CHz-1-imidazol-H 466.2 464.3 I
33 -COOH -N CH3 ~ -H
34 -5-(1,2,3,4--NH-C(O)CH3 -H 388 386 tetrazol I
35 -SO~NHCH3 -NH-N=CH-i erid I
3g -OH -O-CHZCH2-1-imidazolyl-OCH3 40 -S02NH- -O-CH~CH2-1-imidazolyl-H 496 494 CH~CH2-OH
41 -C O NH2 Amino -H 321 42 -SO~NH2 -CH=CH-NH- 381 43 -5-(1,2,3,4--NHCH2-3-pyridyl -H 435 tetrazol I
44 -S02NH2 -NH-CH=CH- 379 morpholin 46 -COOH -H -1-(4-amino)-piperid I
48 - -O-CHZCH2-1-imidazolyl-H 480 478 SON CH3)2 The compounds of formula X2 R$
N \N- _N ~ OCH
R
wherein R3 and R8 are as defined in Table 2, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R ~ Ra MS Data *ES+ *ES-50 -S02NH~ -OH
52 -5- 1,2,3,4-tetrazol-OCH3 421 I
53 -S02NH-c clopro -OCH3 472.2 470.3 I
CH2CH~-OH
56 -S02N(CH3)~ -OCH3 460.3 458.3 The compounds of formula X3 R' R~ Ra I ~\~I ~
N N- 'N \ R9 H H
wherein R', R', R$ and R9 are as defined in Table 3, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R' R R R MS
Data *ES+ *ES-61 -SOZNH-CH2CH2--H -N(CH)--H
O-CH2CH2-OH C(O)CH
62 -S02NH~ -OCH~ -OCH3 -OCH3 -imidazol I
64 -SO2NH-CH2CHz--OCH3 -OCH3 -OCH3 520 518 65 -N(CH3) C(O)CH3-OCH3 -OCH3 -OCH3 424 422 CHzCHzCHzCH3 67 -SOZNHz -OCH3 -H -OCHs 68 -SOzNHz -O-CHzCHz-1- -H -H
imidazol I
69 -CH2CHz-OH -O-CH2CHz-1- -H -H
imidazol I
70 -CH2CHz-OH -OCH3 -H -OCH3 71 -SO2NHz -OH -H -H
72 -O-CHzCHz-OH -O-CH2CHz-1- -H -H
imidazol I
73 -S02NH-2-thiazol-OCH3 -OCH3 -OCH3 515 513 I
The compounds of formula X4 R' R5 / Ra ~ ~I
R2 \ N N_ 'N ~ R9 H H
wherein Rz, R5, R', R$ and R9 are as defined in Table 4, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example Rz R R R R MS Data *ES+ *ES-pro en I
75 -SO2NHz -H -OCH3 -OCH3 -OCH3 76 -OH -H -O-(1-methyl)- -H -H 406.3 404.3 azac clohe t-4.-I
77 -OH -H -O-CH2CHz-OH -OCH3 -H 369 367 78 -SO2NHz -Br -OCH3 -OCH3 -OCH3 510.1! 508.1/
512.1 510.2 79 -S02NHz -H -CH=N-NH- -H 382 80 -S02NHz -CH3 -OCH3 -OCH3 -OCH3 446 4 81 -S02NHz -H -O-CH2CHz-1- -OCH3 -H 482 _ imidazol I _ 82 -OH -H -O-CH2CHz-1- i -OCH3 -H 436.3 434.3 erid I
83 -OH -H -O-CH2CHz-1- -OCH3 -H 419 417 imidazol I
84 -S02NHz -H -O-CH2CHz-1- -H -H 452 450 imidazol I
85 -CH3 -C-_-N-OCH3 -OCH3 -OCH3 392 86 -S02NHz -H -NH-N=CH- -H 382 88 - _CH3 _OCH3 -OCH3 -OCH3 460 458 90 -OH -H -O-CH2CH2-1- i -H -H 406 404 erid I
91 -S02NH-2--H -O-CHzCH2-1- -H -H 492.3 490.3 ro en imidazol I
I
92 -SO2NH2 -Br -O-CHZCHZ-1-(1- -H -H 544.1/542/
meth I -imidazol 546 544.2 I
93 -S02NH2 -H -O-CH2CHa-OH -OCH3 -H
94 -OH -H -O-(1-methyl)- -H -H
azac clo ent-2-I
imidazol I
96 -OH -H -O-CH2CHaCH2-1- -OCH3 -H 433.4 431.4 imidazoi I
CH2CH~CH
100 -S02NH- -CH3 -O-CH~CHZ-1- -OCH~ -H 510 508 CH3 imidaxol 1 101 - -H -O-CH~CHZ-1- -H -H 08 506 S02NHCH2 imidazolyl mor holino 103 -OH -H -NH-N=CH- -H 319 317 imidazol I
106 -SOZNH- - -OCH3 -OCH3 -OCH~ 474.3 472.3 CH3 CH2_ 107 -SO~NHz -H -OCH3 -OCH3 -OCH3 The compounds of formula X5 _16_ R° OCH3 2 ~ I
R R ~R4 N H OCH3 wherein R°, R', R~, R3 and R4 are as defined in Table 5, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R" R' R' R R" MS Data *ES+ *ES-109 -H nitro -H -OH -H 414 412 110 -H -N=CH-CH=CH- -H -H
11_1 -H -CH=N-NH- -H -H 393 391 112 -H -NH-N=CH- -H -H 393 115 -H henyl -H -SO~NH2 -H 508 506 116 ~ -CH3 -H -H -SOZNH2 -H 446 444 The compounds of formula X6 R' R5 R$
N N"N \ R9 H H
wherein R5, R', Ra and R9 are as defined in Table 6, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R R R R *ES+ *ES-117 -CH3 -O-CH2CH2-1-imidazol -H -H 466 I
119 -Br -NH-N=CH- -H 461 120 -CH3 -O-CH2CH2-1-imidazol -OCH3 -H 496 I
122 -CH3 -N=N-NH- -H 397.2 395.
123 -CH3 -O-CH2CH2-1-methyl-imidazol--H -H 480 124 -Br -CH=N-NH- -H 461.3 458.
125 -CH3 -NH-N=CH- -H 396 126 -Br -OCHZCH2-(4-methyl-piperazin--H -H 562/ 560/
1- I) 564 562 The compounds of formula X~
R' R$
~ ~I
R2 \ N NI 'N \
H H
R
wherein R', R2, R3, R' and R$ are as defined in Table 7, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R R R R *ES+ *ES-127 -OCH3 -OH -H -OH , -128 -H -CH3 - -O-CH2CH2-1-imidazolyl-H 466 464 129 -OCH3 -OH -H -O-CHZCH2-1-imidazolyl-130 -OCH3 -OH -H -O-CHzCH2-OH - 399 397 131 -OCH3 -OH -H -O-(1-methyl-azacyclohept-4--H 436 I
132 -CH3 -H -O-CH2CH2-1-imidazolyl-H 466 464 133 -OCH3 -OH -H -O-CHzCH2-(1-methyl)- -H 436 434 azac clo ent-2- I
135 -N=CH-CH=CH- -H -O-CH~CH2-1-imidazolyl-136 -OCH3 -OH -H -O-CH2CH2CH2-1-imidazolyl 463 461 137 -OCH3 -OH -H -O-CH2CH2-1-piperidyl 466.4 464.4 138 -CH=N-NH- -H -NH-N=CH-139 -CH=N-NH- -H -CH-N=NH--18_ 140 -OCH3 -OH -H -O-CHzCH~-1- i erid -H 436 434 I
141 -H -OCH3 - -O-CH2CH~-1-pyrrolidinyl-H 485.3 483.3 SO~NHa 142 -H -OCH3 - -O-CH2CH2-1-pyrrolidinyl-CH3 499.2 497.3 S02NH~
143 -H -OCH3 - -O-CH2CHZCH~-morpholino- 545.2 545.3 S02NHa OCH3 144 -H -OCH(CH3)2- -O-CH~CH~-(4-methyl- - 572.2 570.3 S02NH2 i erazin-1- I OCH3 145 -H -OCH3 - -O-CH2CH2-1-piperidinyl-H 499.2 497.3 146 -CH3 -OCH3 - -O-CH2CH2CH~-1-pyrrolidinyl- 543.2 SO~NH2 .
147 -CH3 -OCH3 - -O-CH2CH~CH2-1-pyrrolidinyl-H 513.2 511.2 SO~NH2 148 -H -OCH(CH~)2- -O-CH2CH2-1-piperidinyl-H 527.2 525.3 149 -H -CH3 - -N(CH3)2 - 429.3 427.3 150 -CH3 -CH3 - -O-CH2CH2CH2-1-pyrrolidinyl- 527.2 525.3 151 -OCH3 -H - -O-CH2CH2CH~-1-pyrrolidinyl- 529.2 527.3 152 -H -F - -N(CH3)2 - 433.1 153 -H -CH3 - -O-CH~CH~-(1-methyl- -H
SO~NH2 yrrolidin-2- I
154 -H -OCH3 - -O-CH2CH2-OH -H 432.2 430.2 155 -H -CH3 - -O-CH~CH2-(1-methyl- - 513.2 511.3 S02NH~ pyrrolidin-2- ! OCH3 156 -OCH~ -H - -O-CHzCH2-1-piperidinyl-H 499.2 497.3 157 -OCH3 -H - -O-CH2CH2-1-pyrrolidinyl- 515.2 513.2 158 -H -CH3 - -O-CH2CH2-OH - 446.2 444.2 159 - -H - -O-CH~CH2-1-pyrrolidinyl-CH3 513.3 511.3 160 -OCH3 -OCH3 - -O-CHZCH2-(4-methyl- - 574,2 572.2 S02NH~ piperazin-1- I OCH3 161 -H -CI - -(4-methyl-piperazin-1-yl)-H 474.5 472.5 162 -H -CH3 - -O-CHzCH2-(4-cyclopentyl--H 552.3 550.3 S02NH2 piperazin-1- I
163 -CH=CH-CH=CH- - -(4-methyl-piperazin-1-yl)-H 490.5 488.4 SO~NH2 164 -H -H - -O-CH2CH2-piperazin-1-yl-H 470.2 468.3 165 -H -OCHs - -H - 402.2 400.2 166 -H -OCHa - -O-CHzCH2-(4-benzyl- -H 590.3 588.3 SO~NH2 i erazin-1- I
167 -CHs -H - -O-CH2CHZ-1-pyrrolidinyl-H 469.2 467.3 S02NH~
168 -Br -H - -O-CH2CH~-1-piperidinyl-H 549.1 547.2 The compounds of formula Xs R~ Ra / l ~ ~I /
R2 ' N NI 'N
H H
R
wherein R', R2, R3 and R8 are as defined in Table 8, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R~ R R *ES+ *ES-~
169 4-morpholino-H -H -H
170 -CH=N-NH- -H -H 363 361 172 -CH3 -H -SO~NH~ -OCH3 446 The compounds of formula X9 CI R' / ~ w ~N /
N NI 'N \ R9 H H
OH
wherein R', R$ and R9 are as defined in Table 9, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Exampl R R R *ES+ *ES-a 173 -O-CH2CH2-1- i erid -OCH3 -H 470.3 468.3 I
174 -O-(1-methyl-azacyclohept-4--H -H 440 I
175 -O-(1-methyl-azacyclopent-2--H -H 440 438 I
176 -O-CH2CH~-CH2-1-imidazol-OCH3 -H 467 465 I
177 -OCH3 -OCH~ -178 -O-CH2CH~-1- 1,2,4-triazol-H -H 424 422 I) 179 -O-CH2CH2-1- i erid -H -H
I
181 -O-CH2CH2-4-mor holino-H -H 442 440 182 -O-CH2CH2CH~-1-imidazol-H -H
I
The compounds of formula X~o N H Rs wherein R', R' and R9 are as defined in Table 10, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
TARS F 1 (t EX R R Re *ES+ *ES-184 -SO~NH~ -O-CH2CH2-1- -H 496.3 494.3 imidazol I
The compounds of formula X~~
N / Rs ~~_I
N NI 'N ~ O
wherein R$ is -OCH3 (Example 185) or -OH (Example 186), may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
The compounds of formula X~Z
R° R7 R1 / Br / N / R$
I ~~ ~ I
~N N N R
H H
wherein R°, R', R', R8 and R9 are as defined in Table 12, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R R7 R R R
194 -H -H -H -H -N CH3 z 196 -H -H -H -OCH(CH3 ~ -H
~
198 -H -H -H -CH=N -NH-199 -H -H -OCHs -CH3 -OCH3 201 -H -H -H -H -_H
- -203 _H -H -H -H _CF3 205 -H -H -H -NH-C H=N-206 -H -H -H -N -CH2CH2CH2-4-morpholino -CH=CH-207 -H -H -CH 2CH2- CH2_ _H
The compounds of formula X~3 R~ / R5 / N / OCH3 ~ I ~~ ~
R ~ ~H N H OCH3 wherein R', R2, R3 and R5 are as defined in Table 13, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R~ RZ R'' R'' *ES+ *ES-208 -H -H -S02NHCH3 -CF3 514.0 209 -H -H -S02NHC3H~ -Br 210 -H -H -S02NH-CH~CH- -Br c clo ro I
212 -H -H -S02N CH3 2 -Br 215 -H -H -S02NHCH3 -Br 216 -CH3 -OCH~ -S02NH2 -H 476 474 217 -H l eridino-S02NH2 -H 515.5 513.4 218 -H morpholin-SO~NH2 -H 517.4 515.4 221 -H -CH3 -SOZNHCH3 -H 460.4 222 -H hen I -SO~NH2 -H 508.2 506.3 The compounds of formula X~4 R?
R5 / Ra I ~~~1 ~
R2 \ N N"N \ R9 H H
wherein R~, R3, R5, R', R$ and R9 are as defined in Table 14, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R R R R R *ES *ES-223 -OCH3 - -H -H -CH=N- 424 S02NH2 N(CH3)-224 -OCH3 - -H -O-CH2CH2-OCH3 -OCH3 -H 476. 474.3 225 -OCH(CH3)~ - -H -O-CH2CH~- -OCH3 -H 551. 555.3 S02NH~ iperidino 2 226 -OCH3 - -H -O-CH2CH2-(4- -H -H 514. 512.3 SO~NHZ methyl-piperaain-1- 3 I
227 -OCH3 - -H -morpholino -OCH3 -H 487. 485.2 S02NH~ 1 228 -CH3 - -H -O-CHZCH2CH~- -OCH3 -H 527.
S02NH2 pi eridino 3 229 -CH3 - -H -O-CH2CH~CH2-1--OCH3 -H 513. 511.3 S02NH2 rrolidin I 2 230 -O-CH2CH2- - -H -H -CH=N- 539 537 OCH3 SOZNH~ N(CH3)-231 -(4-methyl- - -H -OCH3 -OCH3 - 530. 528.4 piperazin-1-yl)SO2NH2 OCH 4 232 -OCH3 - -H -O-CHZCH2-OH -OCH3 -H 462. 460.3 233 -OCH3 - -Br -O-CH2CH~-OCH3 -OCH3 -H
S02NH~
234 -CH3 - -H -O-CHZCH2-(4- -OCH3 -H 528. 526.3 S02NH2 methyl-piperazin-1- 2 235 -CH3 - -H -O- CHZCHZ- -H -H 443. 441,3 SO~NH~ N(CH3 2 2 236 -H - -H -O-CHaCH2-1- -OCH3 -H 485. 483.3 SOZNH2 rrolidin I 2 237 -CH3 - -H -H -N(CH3)- 410 SOZNH2 N=CH-S02NH~ s 239 -CH3 - -Br -O-CH~CH~-OCH3 -OCH3 -H 538/
240 -OCH3 - -H -OCH3 -H -H 402. 400.2 SO~NH2 2 SO2NHz NH-CHZC
H~-ES+ means electrospray MS positive mode ; ES- means electrospray MS negative mode;
and EL means electron impact MS.
The compounds of formula I and their pharmaceutically acceptable salts, exhibit valuable pharmacological properties when tested in in vitro assays, and are therefore useful as pharmaceuticals. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity ofi anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK . This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (/MT) and neuroblastomas. (Duyster J et al. 2001 Oncogene 20, 5623-5637). In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
The ALK inhibitory activity and inhibitory activity against ALK-containing gene fusions of the compounds described herein make them useful pharmaceutical agents for the treatment of proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics;
or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.
In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. Proliferative diseases treated according to the present method include tumors of blood and lymphatic system (e.g. Hodgkin's disease, Non-Hodgkin's lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms, lymphoid leukemia, acute or chronic myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma). Myeloid cancer includes e.g.
acute or chronic myeloid leukaemia.
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
The compound is selectively toxic or more toxic to rapidly propiferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
The compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell, for example ATP and GTP phosphodiesterase inhibitors, protein kinase inhibitors, such as serine, threonine and tyrosine kinase inhibitors, for example, Abelson protein tryosine kinase and the various growth factors, their receptors and kinase inhibitors therefore, such as, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors and the like; methionine aminopeptidase inhibitors, proteasome inhibitors, and cyclooxygenase inhibitors, for example, cyclooxygenase-1 or-2 inhibitors. Such antiproliferative agents further include, aromatase inhibitors, antiestrogens, topoisomerase I
inhibitors, topoisomerase II inhibitors, microtubule active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bengamides, bisphosphonates, antiproliferative antibodies and temozolomide (TEMODAL~).
The term "aromatase inhibitors" as used herein relates to compounds which inhibit the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, vorozole, fadrozole, anastrozole and, very especially, letrozole. A
combination of the invention comprising an antineoplastic agent which is an aromatase inhibitor may particularly be useful for the treatment of hormone receptor positive breast tumors.
The term "antiestrogens" as used herein relates to compounds which antagonize the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
The term "topoisomerase I inhibitors" as used herein includes, but is not limited to topotecan, irinotecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in W099/17804).
The term "topoisomerase II inhibitors" as used herein includes, but is not limited to the antracyclines doxorubicin (including liposomal formulation, e.g. CAELYXTM), epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
The term "microtubule active agents" relates to microtubule stabilizing and microtubule destabilizing agents including, but not limited to the taxanes paclitaxel and docetaxel, the vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolide and epothilones, such as epothilone B
and D.
The term "alkylating agents" as used herein includes, but is not limited to cyclophosphamide, ifosfamide and melphalan.
The term "histone deacetylase inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity.
The term "farnesyl transferase inhibitors" relates to compounds which inhibit the farnesyl transferase and which possess antiproliferative activity.
The term "COX-2 inhibitors" relates to compounds which inhibit the cyclooxygenase type 2 enyzme (COX-2) and which possess antiproliferative activity such as celecoxib (Celebrex~), rofecoxib (Vioxx~) and lumiracoxib (COX189).
The term "MMP inhibitors" relates to compounds which inhibit the matrix metalloproteinase (MMP) and which possess antiproliferative activity.
The term "antineoplastic antimetabolites" includes, but is not limited to 5-fluorouracil, tegafur, capecitabine, cladribine, cytarabine, fludarabine phosphate, fluorouridine, gemcitabine, 6-mercaptopurine, hydroxyurea, methotrexate, edatrexate and salts of such compounds, and furthermore ZD 1694 (RALTITREXEDT""), LY231514 (ALIMTAT""), LY264618 (LOMOTREXOLT"") and OGT719.
The term "platin compounds" as used herein includes, but is not limited to carboplatin, cis-platin and oxaliplatin.
The term "compounds decreasing the protein kinase activity and further anti-angiogenic compounds" as used herein includes, but is not limited to compounds which decrease the activity of e.g. the Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth Factor (EGF), c-Src, protein kinase C, Platelet-derived Growth Factor (PDGF), Bcr-Abl tyrosine kinase, c-kit, Flt-3 and Insulin-like Growth Factor I Receptor (IGF-IR) and Cyclin-dependent kinases (CDKs), and anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity.
_2~_ Compounds which decrease the activity of VEGF are especially compounds which inhibit the VEGF receptor, especially the tyrosine kinase activity of the VEGF receptor, and compounds binding to VEGF, and are in particular those compounds, proteins and monoclonal antibodies generically and specifically disclosed in WO 98/35958 (describing compounds of formula I), WO 00/09495, WO 00/27820, WO 00/59509, WO 98/11223, WO 00/27819, WO 01/55114, WO 01/58899 and EP 0 769 947; those as described by M. Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Nat!. Acad. Sci. USA, vol. 93, pp. 14765-14770, December 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J.
Mordenti et al in Toxicologic Pathology, vol. 27, no. 1, pp 14-21, 1999; in WO
00/37502 and WO 94/10202; AngiostatinT"", described by M. S. O'Reilly et al, Cell 79, 1994, 315-328; and EndostatinT"~, described by M. S. O'Reilly et al, Cell 88, 1997, 277-285;
compounds which decrease the activity of EGF are especially compounds which inhibit the EGF receptor, especially the tyrosine kinase activity of the EGF receptor, and compounds binding to EGF, and are in particular those compounds generically and specifically disclosed in WO 97/02266 (describing compounds of formula IV), EP 0 564 409, WO
99/03854, EP
0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, WO 98/10767, WO 97/30034, WO
97!49688, WO 97/38983 and, especially, WO 96/33980;
compounds which decrease the activity of c-Src include, but are not limited to, compounds inhibiting the c-Src protein tyrosine kinase activity as defined below and to SH2 interaction inhibitors such as those disclosed in W097/07131 and W097/08193;
compounds inhibiting the c-Src protein tyrosine kinase activity include, but are not limited to, compounds belonging to the structure classes of pyrrolopyrimidines, especially pyrrolo[2,3-d]pyrimidines, purines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines and pyridopyrimidines, especially pyridoj2,3-d]pyrimidines. Preferably, the term relates to those compounds disclosed in WO
96/10028, WO 97128161, W097/32879 and WO97/49706;
compounds which decreases the activity of the protein kinase C are especially those staurosporine derivatives disclosed in EP 0 296 110 (pharmaceutical preparation described in WO 00/48571 ) which compounds are protein kinase C inhibitors;
further specific compounds that decrease protein kinase activity and which may also be used in combination with the compounds of the present invention are Imatinib (Gleevec~/Glivec~), PKC412, IressaT"" (ZD1839}, PKI166, PTK787, ZD6474, GW2016, CHIR-200131, CEP-7055/CEP-5214, CP-547632 and KRN-633;
_~o~_ anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity include, but are not limited to e.g. thalidomide (THAL~MID), celecoxib (Celebrex), SU5416 and ZD6126.
The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin is disclosed in US 4,100,274.
The term "anti-androgens" as used herein includes, but is not limited to bicalutamide (CASODEXTM), which can be formulated, e.g. as disclosed in US 4,636,505.
The term "bengamides" relates to bengamides and derivatives thereof having aniproliferative properties.
The term "bisphosphonates" as used herein includes, but is not limited to etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid and zoledronic acid.
The term "antiproliferative antibodies" as used herein includes, but is not limited to trastuzumab (HerceptinTM), Trastuzumab-DM1, erlotinib (TarcevaTM), bevacizumab (AvastinTM
), rituximab (Rituxan~), PR064553 (anti-CD40) and 2C4 Antibody.
The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
The compositions of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising an agent of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance. Topical administration is e.g. to the skin. A further form of topical administration is to the eye.
The compounds of formula f may be administered in free form or in pharmaceutically acceptable salt form, e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
The inhibition of ALK tyrosine kinase activity is measured using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R
kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). The table below reports the fC50 values for several compounds of the present invention.
Each compound is tested twice, once each with two different preparations of ALK.
compound IC50 NM
Ex.48 0.048 Ex.48 0.083 Ex.58 0.046 Ex.58 0.090 Ex. 56 0.18 Ex. 56-~ --0.086 The compounds of formula I potently inhibit the growth of human NPM-ALK
overexpressing marine BaF3 cells. The expression of NPM-ALK is achieved by transfecting the BaF3 cell line with an expression vector pCIneoT"" (Promega Corp., Madison WI, USA ) coding for NPM-ALK and subsequent selection of 6418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast NPM-ALK expressing BaF3 cells ( named BaF3-NPM-ALK) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and result in antiproliferative activity. The antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3 which provides growth signals through an NPM-ALK independent mechanism. [for an analogous cell system using FLT3 kinase see E Weisberg et al. Cancer Cell; 1, 433-443 (2002). The inhibitory activity of the compounds of formula I is determined, briefly, as follows: BaF3-NPM-ALK cells (15 000/microtitre plate well) are transferred to 96-well microtitre plates. The test compounds [dissolved in dimethyl sulfoxide (DMSO)] are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1 (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles.
The growth of the BaF3-NPM-ALK cells is measured by means of YoproT''" staining (T fdziorek et al. J.
Immunol. Methods; 185:249-58 [1995]) : 25 p1 of lysis buffer consisting of 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4 % NP40, 20 mM EDTA and 20 mM was added to each well. Cell lysis was completed within 60 min at room temperature and total amount of Yopro bound to DNA was determined by measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and Emission (nm) 530/25.
ICSOvalues are determined by a computer-aided system using the formula:
ICSO = [(ABStest - ABSs~~)/(ABS~ontro~ - ABSstart)] x 100.
The ICSO value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor. The compounds of formula I exhibit inhibitory activity with an IC5o in the range from approximately 0.01 to 1 ~,M.
The antiproliferative action of the compounds of formula I can also be determined in the human KARPAS-299 lympoma cell line ( described in WG Dirks et al. Int. J.
Cancer 100, 49-56 (2002) using the same methodology described above for the BaF3-NPM-ALK cell line.
The compounds of formula I exhibit inhibitory activity with an ICSO in the range from approximately 0.01 to 1 wM.
The following compounds are tested in the cellular assays in the BaF3 cell lines and the KARPAS-299 cell line as described above:
BaF3 BaF3 I<ARPAS-NPM-ALK NPM-ALK
with IL3 without IC50 (NM) IC50 (NM) IC50 (pM
Ex. 56 2.7 0.41 0.15 Ex.58 2.6 0.56 0.33 Ex.48 1.4 0.55 0.27
_ _ _ -SO2NH2 -O-CH2CH2CH~-1-imidazol-OCH3 496 494 11 -S02NH2 I -OCH~ 499.2497.3 -O-2- 1- i arid I -eth I
12 -SOzNH2 -O-CH2CHz-1-methyl- -H 4fi6 464 imidazoi-1- I
13 -OH -O-2-[1- 1,2,4-triazolyl)-H 390 388 -eth I
14 -OH -O-2-h drox eth I -OCH3 369.4367.3 -SO~NH2 -O-2-h dro eth I -OCH3 431 16 -SO~NH2 -O-CH2CH2-1-imidazol -OCH3 I
17 -S02NH2 -O-2- 1-(1,2,4-triazol-H 452 I -eth I
18 -S02NH~ -NH-N=N- 381 19 -SO2NHCH3 -O-CH2CHz-1-imidazol -OCH3 496 494 I
-S02NH2 -O-2-(1-pi arid I -eth-H 469 467 I
21 -S02NH2 -O-CH2CH2-1-imidazol -H 452 450 I
22 -OH -O-2- 1- iperid I)-eth-H 406 I
23 -COOH -4-mor holino -H
24 -OH -O-CH2CH~CH~-1-imidazol-OCH3 433 431 I
-S02NHCH3 -CH=N-NH- 396 394 26 -S02NH2 -O-2- 4-mor holino -H 471 469 eth 1 28 -OH -O-2- 4-mor holino -H 408 406 eth I
29 -SOZNH2 -CH=N-NH- 381 -S02NHCH3 -O-CH2CH2-1-imidazol I -H
31 -COON Amino -H 322 32 -SO2NH2 -O-CH~CH2CHz-1-imidazol-H 466.2 464.3 I
33 -COOH -N CH3 ~ -H
34 -5-(1,2,3,4--NH-C(O)CH3 -H 388 386 tetrazol I
35 -SO~NHCH3 -NH-N=CH-i erid I
3g -OH -O-CHZCH2-1-imidazolyl-OCH3 40 -S02NH- -O-CH~CH2-1-imidazolyl-H 496 494 CH~CH2-OH
41 -C O NH2 Amino -H 321 42 -SO~NH2 -CH=CH-NH- 381 43 -5-(1,2,3,4--NHCH2-3-pyridyl -H 435 tetrazol I
44 -S02NH2 -NH-CH=CH- 379 morpholin 46 -COOH -H -1-(4-amino)-piperid I
48 - -O-CHZCH2-1-imidazolyl-H 480 478 SON CH3)2 The compounds of formula X2 R$
N \N- _N ~ OCH
R
wherein R3 and R8 are as defined in Table 2, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R ~ Ra MS Data *ES+ *ES-50 -S02NH~ -OH
52 -5- 1,2,3,4-tetrazol-OCH3 421 I
53 -S02NH-c clopro -OCH3 472.2 470.3 I
CH2CH~-OH
56 -S02N(CH3)~ -OCH3 460.3 458.3 The compounds of formula X3 R' R~ Ra I ~\~I ~
N N- 'N \ R9 H H
wherein R', R', R$ and R9 are as defined in Table 3, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R' R R R MS
Data *ES+ *ES-61 -SOZNH-CH2CH2--H -N(CH)--H
O-CH2CH2-OH C(O)CH
62 -S02NH~ -OCH~ -OCH3 -OCH3 -imidazol I
64 -SO2NH-CH2CHz--OCH3 -OCH3 -OCH3 520 518 65 -N(CH3) C(O)CH3-OCH3 -OCH3 -OCH3 424 422 CHzCHzCHzCH3 67 -SOZNHz -OCH3 -H -OCHs 68 -SOzNHz -O-CHzCHz-1- -H -H
imidazol I
69 -CH2CHz-OH -O-CH2CHz-1- -H -H
imidazol I
70 -CH2CHz-OH -OCH3 -H -OCH3 71 -SO2NHz -OH -H -H
72 -O-CHzCHz-OH -O-CH2CHz-1- -H -H
imidazol I
73 -S02NH-2-thiazol-OCH3 -OCH3 -OCH3 515 513 I
The compounds of formula X4 R' R5 / Ra ~ ~I
R2 \ N N_ 'N ~ R9 H H
wherein Rz, R5, R', R$ and R9 are as defined in Table 4, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example Rz R R R R MS Data *ES+ *ES-pro en I
75 -SO2NHz -H -OCH3 -OCH3 -OCH3 76 -OH -H -O-(1-methyl)- -H -H 406.3 404.3 azac clohe t-4.-I
77 -OH -H -O-CH2CHz-OH -OCH3 -H 369 367 78 -SO2NHz -Br -OCH3 -OCH3 -OCH3 510.1! 508.1/
512.1 510.2 79 -S02NHz -H -CH=N-NH- -H 382 80 -S02NHz -CH3 -OCH3 -OCH3 -OCH3 446 4 81 -S02NHz -H -O-CH2CHz-1- -OCH3 -H 482 _ imidazol I _ 82 -OH -H -O-CH2CHz-1- i -OCH3 -H 436.3 434.3 erid I
83 -OH -H -O-CH2CHz-1- -OCH3 -H 419 417 imidazol I
84 -S02NHz -H -O-CH2CHz-1- -H -H 452 450 imidazol I
85 -CH3 -C-_-N-OCH3 -OCH3 -OCH3 392 86 -S02NHz -H -NH-N=CH- -H 382 88 - _CH3 _OCH3 -OCH3 -OCH3 460 458 90 -OH -H -O-CH2CH2-1- i -H -H 406 404 erid I
91 -S02NH-2--H -O-CHzCH2-1- -H -H 492.3 490.3 ro en imidazol I
I
92 -SO2NH2 -Br -O-CHZCHZ-1-(1- -H -H 544.1/542/
meth I -imidazol 546 544.2 I
93 -S02NH2 -H -O-CH2CHa-OH -OCH3 -H
94 -OH -H -O-(1-methyl)- -H -H
azac clo ent-2-I
imidazol I
96 -OH -H -O-CH2CHaCH2-1- -OCH3 -H 433.4 431.4 imidazoi I
CH2CH~CH
100 -S02NH- -CH3 -O-CH~CHZ-1- -OCH~ -H 510 508 CH3 imidaxol 1 101 - -H -O-CH~CHZ-1- -H -H 08 506 S02NHCH2 imidazolyl mor holino 103 -OH -H -NH-N=CH- -H 319 317 imidazol I
106 -SOZNH- - -OCH3 -OCH3 -OCH~ 474.3 472.3 CH3 CH2_ 107 -SO~NHz -H -OCH3 -OCH3 -OCH3 The compounds of formula X5 _16_ R° OCH3 2 ~ I
R R ~R4 N H OCH3 wherein R°, R', R~, R3 and R4 are as defined in Table 5, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R" R' R' R R" MS Data *ES+ *ES-109 -H nitro -H -OH -H 414 412 110 -H -N=CH-CH=CH- -H -H
11_1 -H -CH=N-NH- -H -H 393 391 112 -H -NH-N=CH- -H -H 393 115 -H henyl -H -SO~NH2 -H 508 506 116 ~ -CH3 -H -H -SOZNH2 -H 446 444 The compounds of formula X6 R' R5 R$
N N"N \ R9 H H
wherein R5, R', Ra and R9 are as defined in Table 6, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R R R R *ES+ *ES-117 -CH3 -O-CH2CH2-1-imidazol -H -H 466 I
119 -Br -NH-N=CH- -H 461 120 -CH3 -O-CH2CH2-1-imidazol -OCH3 -H 496 I
122 -CH3 -N=N-NH- -H 397.2 395.
123 -CH3 -O-CH2CH2-1-methyl-imidazol--H -H 480 124 -Br -CH=N-NH- -H 461.3 458.
125 -CH3 -NH-N=CH- -H 396 126 -Br -OCHZCH2-(4-methyl-piperazin--H -H 562/ 560/
1- I) 564 562 The compounds of formula X~
R' R$
~ ~I
R2 \ N NI 'N \
H H
R
wherein R', R2, R3, R' and R$ are as defined in Table 7, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R R R R *ES+ *ES-127 -OCH3 -OH -H -OH , -128 -H -CH3 - -O-CH2CH2-1-imidazolyl-H 466 464 129 -OCH3 -OH -H -O-CHZCH2-1-imidazolyl-130 -OCH3 -OH -H -O-CHzCH2-OH - 399 397 131 -OCH3 -OH -H -O-(1-methyl-azacyclohept-4--H 436 I
132 -CH3 -H -O-CH2CH2-1-imidazolyl-H 466 464 133 -OCH3 -OH -H -O-CHzCH2-(1-methyl)- -H 436 434 azac clo ent-2- I
135 -N=CH-CH=CH- -H -O-CH~CH2-1-imidazolyl-136 -OCH3 -OH -H -O-CH2CH2CH2-1-imidazolyl 463 461 137 -OCH3 -OH -H -O-CH2CH2-1-piperidyl 466.4 464.4 138 -CH=N-NH- -H -NH-N=CH-139 -CH=N-NH- -H -CH-N=NH--18_ 140 -OCH3 -OH -H -O-CHzCH~-1- i erid -H 436 434 I
141 -H -OCH3 - -O-CH2CH~-1-pyrrolidinyl-H 485.3 483.3 SO~NHa 142 -H -OCH3 - -O-CH2CH2-1-pyrrolidinyl-CH3 499.2 497.3 S02NH~
143 -H -OCH3 - -O-CH2CHZCH~-morpholino- 545.2 545.3 S02NHa OCH3 144 -H -OCH(CH3)2- -O-CH~CH~-(4-methyl- - 572.2 570.3 S02NH2 i erazin-1- I OCH3 145 -H -OCH3 - -O-CH2CH2-1-piperidinyl-H 499.2 497.3 146 -CH3 -OCH3 - -O-CH2CH2CH~-1-pyrrolidinyl- 543.2 SO~NH2 .
147 -CH3 -OCH3 - -O-CH2CH~CH2-1-pyrrolidinyl-H 513.2 511.2 SO~NH2 148 -H -OCH(CH~)2- -O-CH2CH2-1-piperidinyl-H 527.2 525.3 149 -H -CH3 - -N(CH3)2 - 429.3 427.3 150 -CH3 -CH3 - -O-CH2CH2CH2-1-pyrrolidinyl- 527.2 525.3 151 -OCH3 -H - -O-CH2CH2CH~-1-pyrrolidinyl- 529.2 527.3 152 -H -F - -N(CH3)2 - 433.1 153 -H -CH3 - -O-CH~CH~-(1-methyl- -H
SO~NH2 yrrolidin-2- I
154 -H -OCH3 - -O-CH2CH2-OH -H 432.2 430.2 155 -H -CH3 - -O-CH~CH2-(1-methyl- - 513.2 511.3 S02NH~ pyrrolidin-2- ! OCH3 156 -OCH~ -H - -O-CHzCH2-1-piperidinyl-H 499.2 497.3 157 -OCH3 -H - -O-CH2CH2-1-pyrrolidinyl- 515.2 513.2 158 -H -CH3 - -O-CH2CH2-OH - 446.2 444.2 159 - -H - -O-CH~CH2-1-pyrrolidinyl-CH3 513.3 511.3 160 -OCH3 -OCH3 - -O-CHZCH2-(4-methyl- - 574,2 572.2 S02NH~ piperazin-1- I OCH3 161 -H -CI - -(4-methyl-piperazin-1-yl)-H 474.5 472.5 162 -H -CH3 - -O-CHzCH2-(4-cyclopentyl--H 552.3 550.3 S02NH2 piperazin-1- I
163 -CH=CH-CH=CH- - -(4-methyl-piperazin-1-yl)-H 490.5 488.4 SO~NH2 164 -H -H - -O-CH2CH2-piperazin-1-yl-H 470.2 468.3 165 -H -OCHs - -H - 402.2 400.2 166 -H -OCHa - -O-CHzCH2-(4-benzyl- -H 590.3 588.3 SO~NH2 i erazin-1- I
167 -CHs -H - -O-CH2CHZ-1-pyrrolidinyl-H 469.2 467.3 S02NH~
168 -Br -H - -O-CH2CH~-1-piperidinyl-H 549.1 547.2 The compounds of formula Xs R~ Ra / l ~ ~I /
R2 ' N NI 'N
H H
R
wherein R', R2, R3 and R8 are as defined in Table 8, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R~ R R *ES+ *ES-~
169 4-morpholino-H -H -H
170 -CH=N-NH- -H -H 363 361 172 -CH3 -H -SO~NH~ -OCH3 446 The compounds of formula X9 CI R' / ~ w ~N /
N NI 'N \ R9 H H
OH
wherein R', R$ and R9 are as defined in Table 9, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Exampl R R R *ES+ *ES-a 173 -O-CH2CH2-1- i erid -OCH3 -H 470.3 468.3 I
174 -O-(1-methyl-azacyclohept-4--H -H 440 I
175 -O-(1-methyl-azacyclopent-2--H -H 440 438 I
176 -O-CH2CH~-CH2-1-imidazol-OCH3 -H 467 465 I
177 -OCH3 -OCH~ -178 -O-CH2CH~-1- 1,2,4-triazol-H -H 424 422 I) 179 -O-CH2CH2-1- i erid -H -H
I
181 -O-CH2CH2-4-mor holino-H -H 442 440 182 -O-CH2CH2CH~-1-imidazol-H -H
I
The compounds of formula X~o N H Rs wherein R', R' and R9 are as defined in Table 10, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
TARS F 1 (t EX R R Re *ES+ *ES-184 -SO~NH~ -O-CH2CH2-1- -H 496.3 494.3 imidazol I
The compounds of formula X~~
N / Rs ~~_I
N NI 'N ~ O
wherein R$ is -OCH3 (Example 185) or -OH (Example 186), may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
The compounds of formula X~Z
R° R7 R1 / Br / N / R$
I ~~ ~ I
~N N N R
H H
wherein R°, R', R', R8 and R9 are as defined in Table 12, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R R7 R R R
194 -H -H -H -H -N CH3 z 196 -H -H -H -OCH(CH3 ~ -H
~
198 -H -H -H -CH=N -NH-199 -H -H -OCHs -CH3 -OCH3 201 -H -H -H -H -_H
- -203 _H -H -H -H _CF3 205 -H -H -H -NH-C H=N-206 -H -H -H -N -CH2CH2CH2-4-morpholino -CH=CH-207 -H -H -CH 2CH2- CH2_ _H
The compounds of formula X~3 R~ / R5 / N / OCH3 ~ I ~~ ~
R ~ ~H N H OCH3 wherein R', R2, R3 and R5 are as defined in Table 13, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Example R~ RZ R'' R'' *ES+ *ES-208 -H -H -S02NHCH3 -CF3 514.0 209 -H -H -S02NHC3H~ -Br 210 -H -H -S02NH-CH~CH- -Br c clo ro I
212 -H -H -S02N CH3 2 -Br 215 -H -H -S02NHCH3 -Br 216 -CH3 -OCH~ -S02NH2 -H 476 474 217 -H l eridino-S02NH2 -H 515.5 513.4 218 -H morpholin-SO~NH2 -H 517.4 515.4 221 -H -CH3 -SOZNHCH3 -H 460.4 222 -H hen I -SO~NH2 -H 508.2 506.3 The compounds of formula X~4 R?
R5 / Ra I ~~~1 ~
R2 \ N N"N \ R9 H H
wherein R~, R3, R5, R', R$ and R9 are as defined in Table 14, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.
Ex R R R R R R *ES *ES-223 -OCH3 - -H -H -CH=N- 424 S02NH2 N(CH3)-224 -OCH3 - -H -O-CH2CH2-OCH3 -OCH3 -H 476. 474.3 225 -OCH(CH3)~ - -H -O-CH2CH~- -OCH3 -H 551. 555.3 S02NH~ iperidino 2 226 -OCH3 - -H -O-CH2CH2-(4- -H -H 514. 512.3 SO~NHZ methyl-piperaain-1- 3 I
227 -OCH3 - -H -morpholino -OCH3 -H 487. 485.2 S02NH~ 1 228 -CH3 - -H -O-CHZCH2CH~- -OCH3 -H 527.
S02NH2 pi eridino 3 229 -CH3 - -H -O-CH2CH~CH2-1--OCH3 -H 513. 511.3 S02NH2 rrolidin I 2 230 -O-CH2CH2- - -H -H -CH=N- 539 537 OCH3 SOZNH~ N(CH3)-231 -(4-methyl- - -H -OCH3 -OCH3 - 530. 528.4 piperazin-1-yl)SO2NH2 OCH 4 232 -OCH3 - -H -O-CHZCH2-OH -OCH3 -H 462. 460.3 233 -OCH3 - -Br -O-CH2CH~-OCH3 -OCH3 -H
S02NH~
234 -CH3 - -H -O-CHZCH2-(4- -OCH3 -H 528. 526.3 S02NH2 methyl-piperazin-1- 2 235 -CH3 - -H -O- CHZCHZ- -H -H 443. 441,3 SO~NH~ N(CH3 2 2 236 -H - -H -O-CHaCH2-1- -OCH3 -H 485. 483.3 SOZNH2 rrolidin I 2 237 -CH3 - -H -H -N(CH3)- 410 SOZNH2 N=CH-S02NH~ s 239 -CH3 - -Br -O-CH~CH~-OCH3 -OCH3 -H 538/
240 -OCH3 - -H -OCH3 -H -H 402. 400.2 SO~NH2 2 SO2NHz NH-CHZC
H~-ES+ means electrospray MS positive mode ; ES- means electrospray MS negative mode;
and EL means electron impact MS.
The compounds of formula I and their pharmaceutically acceptable salts, exhibit valuable pharmacological properties when tested in in vitro assays, and are therefore useful as pharmaceuticals. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity ofi anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK . This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (/MT) and neuroblastomas. (Duyster J et al. 2001 Oncogene 20, 5623-5637). In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
The ALK inhibitory activity and inhibitory activity against ALK-containing gene fusions of the compounds described herein make them useful pharmaceutical agents for the treatment of proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics;
or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.
In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. Proliferative diseases treated according to the present method include tumors of blood and lymphatic system (e.g. Hodgkin's disease, Non-Hodgkin's lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms, lymphoid leukemia, acute or chronic myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma). Myeloid cancer includes e.g.
acute or chronic myeloid leukaemia.
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
The compound is selectively toxic or more toxic to rapidly propiferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
The compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell, for example ATP and GTP phosphodiesterase inhibitors, protein kinase inhibitors, such as serine, threonine and tyrosine kinase inhibitors, for example, Abelson protein tryosine kinase and the various growth factors, their receptors and kinase inhibitors therefore, such as, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors and the like; methionine aminopeptidase inhibitors, proteasome inhibitors, and cyclooxygenase inhibitors, for example, cyclooxygenase-1 or-2 inhibitors. Such antiproliferative agents further include, aromatase inhibitors, antiestrogens, topoisomerase I
inhibitors, topoisomerase II inhibitors, microtubule active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bengamides, bisphosphonates, antiproliferative antibodies and temozolomide (TEMODAL~).
The term "aromatase inhibitors" as used herein relates to compounds which inhibit the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, vorozole, fadrozole, anastrozole and, very especially, letrozole. A
combination of the invention comprising an antineoplastic agent which is an aromatase inhibitor may particularly be useful for the treatment of hormone receptor positive breast tumors.
The term "antiestrogens" as used herein relates to compounds which antagonize the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
The term "topoisomerase I inhibitors" as used herein includes, but is not limited to topotecan, irinotecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in W099/17804).
The term "topoisomerase II inhibitors" as used herein includes, but is not limited to the antracyclines doxorubicin (including liposomal formulation, e.g. CAELYXTM), epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
The term "microtubule active agents" relates to microtubule stabilizing and microtubule destabilizing agents including, but not limited to the taxanes paclitaxel and docetaxel, the vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolide and epothilones, such as epothilone B
and D.
The term "alkylating agents" as used herein includes, but is not limited to cyclophosphamide, ifosfamide and melphalan.
The term "histone deacetylase inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity.
The term "farnesyl transferase inhibitors" relates to compounds which inhibit the farnesyl transferase and which possess antiproliferative activity.
The term "COX-2 inhibitors" relates to compounds which inhibit the cyclooxygenase type 2 enyzme (COX-2) and which possess antiproliferative activity such as celecoxib (Celebrex~), rofecoxib (Vioxx~) and lumiracoxib (COX189).
The term "MMP inhibitors" relates to compounds which inhibit the matrix metalloproteinase (MMP) and which possess antiproliferative activity.
The term "antineoplastic antimetabolites" includes, but is not limited to 5-fluorouracil, tegafur, capecitabine, cladribine, cytarabine, fludarabine phosphate, fluorouridine, gemcitabine, 6-mercaptopurine, hydroxyurea, methotrexate, edatrexate and salts of such compounds, and furthermore ZD 1694 (RALTITREXEDT""), LY231514 (ALIMTAT""), LY264618 (LOMOTREXOLT"") and OGT719.
The term "platin compounds" as used herein includes, but is not limited to carboplatin, cis-platin and oxaliplatin.
The term "compounds decreasing the protein kinase activity and further anti-angiogenic compounds" as used herein includes, but is not limited to compounds which decrease the activity of e.g. the Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth Factor (EGF), c-Src, protein kinase C, Platelet-derived Growth Factor (PDGF), Bcr-Abl tyrosine kinase, c-kit, Flt-3 and Insulin-like Growth Factor I Receptor (IGF-IR) and Cyclin-dependent kinases (CDKs), and anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity.
_2~_ Compounds which decrease the activity of VEGF are especially compounds which inhibit the VEGF receptor, especially the tyrosine kinase activity of the VEGF receptor, and compounds binding to VEGF, and are in particular those compounds, proteins and monoclonal antibodies generically and specifically disclosed in WO 98/35958 (describing compounds of formula I), WO 00/09495, WO 00/27820, WO 00/59509, WO 98/11223, WO 00/27819, WO 01/55114, WO 01/58899 and EP 0 769 947; those as described by M. Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Nat!. Acad. Sci. USA, vol. 93, pp. 14765-14770, December 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J.
Mordenti et al in Toxicologic Pathology, vol. 27, no. 1, pp 14-21, 1999; in WO
00/37502 and WO 94/10202; AngiostatinT"", described by M. S. O'Reilly et al, Cell 79, 1994, 315-328; and EndostatinT"~, described by M. S. O'Reilly et al, Cell 88, 1997, 277-285;
compounds which decrease the activity of EGF are especially compounds which inhibit the EGF receptor, especially the tyrosine kinase activity of the EGF receptor, and compounds binding to EGF, and are in particular those compounds generically and specifically disclosed in WO 97/02266 (describing compounds of formula IV), EP 0 564 409, WO
99/03854, EP
0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, WO 98/10767, WO 97/30034, WO
97!49688, WO 97/38983 and, especially, WO 96/33980;
compounds which decrease the activity of c-Src include, but are not limited to, compounds inhibiting the c-Src protein tyrosine kinase activity as defined below and to SH2 interaction inhibitors such as those disclosed in W097/07131 and W097/08193;
compounds inhibiting the c-Src protein tyrosine kinase activity include, but are not limited to, compounds belonging to the structure classes of pyrrolopyrimidines, especially pyrrolo[2,3-d]pyrimidines, purines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines and pyridopyrimidines, especially pyridoj2,3-d]pyrimidines. Preferably, the term relates to those compounds disclosed in WO
96/10028, WO 97128161, W097/32879 and WO97/49706;
compounds which decreases the activity of the protein kinase C are especially those staurosporine derivatives disclosed in EP 0 296 110 (pharmaceutical preparation described in WO 00/48571 ) which compounds are protein kinase C inhibitors;
further specific compounds that decrease protein kinase activity and which may also be used in combination with the compounds of the present invention are Imatinib (Gleevec~/Glivec~), PKC412, IressaT"" (ZD1839}, PKI166, PTK787, ZD6474, GW2016, CHIR-200131, CEP-7055/CEP-5214, CP-547632 and KRN-633;
_~o~_ anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity include, but are not limited to e.g. thalidomide (THAL~MID), celecoxib (Celebrex), SU5416 and ZD6126.
The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin is disclosed in US 4,100,274.
The term "anti-androgens" as used herein includes, but is not limited to bicalutamide (CASODEXTM), which can be formulated, e.g. as disclosed in US 4,636,505.
The term "bengamides" relates to bengamides and derivatives thereof having aniproliferative properties.
The term "bisphosphonates" as used herein includes, but is not limited to etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid and zoledronic acid.
The term "antiproliferative antibodies" as used herein includes, but is not limited to trastuzumab (HerceptinTM), Trastuzumab-DM1, erlotinib (TarcevaTM), bevacizumab (AvastinTM
), rituximab (Rituxan~), PR064553 (anti-CD40) and 2C4 Antibody.
The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
The compositions of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising an agent of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance. Topical administration is e.g. to the skin. A further form of topical administration is to the eye.
The compounds of formula f may be administered in free form or in pharmaceutically acceptable salt form, e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
The inhibition of ALK tyrosine kinase activity is measured using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R
kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). The table below reports the fC50 values for several compounds of the present invention.
Each compound is tested twice, once each with two different preparations of ALK.
compound IC50 NM
Ex.48 0.048 Ex.48 0.083 Ex.58 0.046 Ex.58 0.090 Ex. 56 0.18 Ex. 56-~ --0.086 The compounds of formula I potently inhibit the growth of human NPM-ALK
overexpressing marine BaF3 cells. The expression of NPM-ALK is achieved by transfecting the BaF3 cell line with an expression vector pCIneoT"" (Promega Corp., Madison WI, USA ) coding for NPM-ALK and subsequent selection of 6418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast NPM-ALK expressing BaF3 cells ( named BaF3-NPM-ALK) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and result in antiproliferative activity. The antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3 which provides growth signals through an NPM-ALK independent mechanism. [for an analogous cell system using FLT3 kinase see E Weisberg et al. Cancer Cell; 1, 433-443 (2002). The inhibitory activity of the compounds of formula I is determined, briefly, as follows: BaF3-NPM-ALK cells (15 000/microtitre plate well) are transferred to 96-well microtitre plates. The test compounds [dissolved in dimethyl sulfoxide (DMSO)] are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1 (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles.
The growth of the BaF3-NPM-ALK cells is measured by means of YoproT''" staining (T fdziorek et al. J.
Immunol. Methods; 185:249-58 [1995]) : 25 p1 of lysis buffer consisting of 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4 % NP40, 20 mM EDTA and 20 mM was added to each well. Cell lysis was completed within 60 min at room temperature and total amount of Yopro bound to DNA was determined by measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and Emission (nm) 530/25.
ICSOvalues are determined by a computer-aided system using the formula:
ICSO = [(ABStest - ABSs~~)/(ABS~ontro~ - ABSstart)] x 100.
The ICSO value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor. The compounds of formula I exhibit inhibitory activity with an IC5o in the range from approximately 0.01 to 1 ~,M.
The antiproliferative action of the compounds of formula I can also be determined in the human KARPAS-299 lympoma cell line ( described in WG Dirks et al. Int. J.
Cancer 100, 49-56 (2002) using the same methodology described above for the BaF3-NPM-ALK cell line.
The compounds of formula I exhibit inhibitory activity with an ICSO in the range from approximately 0.01 to 1 wM.
The following compounds are tested in the cellular assays in the BaF3 cell lines and the KARPAS-299 cell line as described above:
BaF3 BaF3 I<ARPAS-NPM-ALK NPM-ALK
with IL3 without IC50 (NM) IC50 (NM) IC50 (pM
Ex. 56 2.7 0.41 0.15 Ex.58 2.6 0.56 0.33 Ex.48 1.4 0.55 0.27
Claims (6)
1. A method of treating or preventing a condition susceptible to treatment with an ALK
inhibiting agent which comprises inhibiting ALK or a gene fusion thereof with a compound of formula I
wherein X is =CR0- or =N-;
each of R0, R1, R2, R3 and R4 independently is hydrogen; hydroxy; C1-C8alkyl;
C2-C8alkenyl;
C3-C8cycloalkyl; C3-C8cycloalkyl-C1-C8alkyl; hydroxyC1-C8alkyl; C1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkoxyC1-C8alkyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C1-C8alkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R1, R2 and R3, independently, is halogen; halo-C1-C8alkyl; C1-C8alkoxy; halo-C1-C8alkoxy; hydroxyC1-C8alkoxy; C1-C8alkoxyC1-C8alkoxy; aryl; arylC1-C8alkoxy;
heteroaryl; heteroaryl-C1-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-C8alkoxycarbonyl; C2-C8alkylcarbonyl; -N(C1-C8alkyl)C(O) C1-C8alkyl; -N(R10)R11;
-CON(R10)R11; -SO2N(R10)R11; or -C1-C4-alkylene-SO2N(R10)R11; wherein each of R10 and R11 independently is hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl; C3-C8cycloalkyl;
C3-C8cycloalkyl-C1-C8alkyl; C1-C8alkoxyC1-C8alkyl; hydroxyC1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkyl; (C1-C8alkyl)-carbonyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C2-C8alkoxycarbonyl; or 5 to membered heterocyclic ring;
or R1 and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C1-C8alkyl; halo-C1-C8alkyl;
C2-C8alkenyl; C1-C8alkynyl; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl; C5-C10arylC1-C8alkyl;
each of R7, R8 and R9 is independently hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl;
halo-C1-C8alkyl; C1-C8alkoxy; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl;
arylC1-C8alkyl;
-Y-R12 wherein Y is a direct bond or O and R12 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxy; (C1-C8alkoxy)-carbonyl; -N(C1-8alkyl)-CO-NR10R11; -CONR10R11 -N(R10)(R11);
-SO2N(R10)R11; R7 and R8 or R8 and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form.
inhibiting agent which comprises inhibiting ALK or a gene fusion thereof with a compound of formula I
wherein X is =CR0- or =N-;
each of R0, R1, R2, R3 and R4 independently is hydrogen; hydroxy; C1-C8alkyl;
C2-C8alkenyl;
C3-C8cycloalkyl; C3-C8cycloalkyl-C1-C8alkyl; hydroxyC1-C8alkyl; C1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkoxyC1-C8alkyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C1-C8alkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R1, R2 and R3, independently, is halogen; halo-C1-C8alkyl; C1-C8alkoxy; halo-C1-C8alkoxy; hydroxyC1-C8alkoxy; C1-C8alkoxyC1-C8alkoxy; aryl; arylC1-C8alkoxy;
heteroaryl; heteroaryl-C1-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-C8alkoxycarbonyl; C2-C8alkylcarbonyl; -N(C1-C8alkyl)C(O) C1-C8alkyl; -N(R10)R11;
-CON(R10)R11; -SO2N(R10)R11; or -C1-C4-alkylene-SO2N(R10)R11; wherein each of R10 and R11 independently is hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl; C3-C8cycloalkyl;
C3-C8cycloalkyl-C1-C8alkyl; C1-C8alkoxyC1-C8alkyl; hydroxyC1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkyl; (C1-C8alkyl)-carbonyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C2-C8alkoxycarbonyl; or 5 to membered heterocyclic ring;
or R1 and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C1-C8alkyl; halo-C1-C8alkyl;
C2-C8alkenyl; C1-C8alkynyl; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl; C5-C10arylC1-C8alkyl;
each of R7, R8 and R9 is independently hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl;
halo-C1-C8alkyl; C1-C8alkoxy; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl;
arylC1-C8alkyl;
-Y-R12 wherein Y is a direct bond or O and R12 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxy; (C1-C8alkoxy)-carbonyl; -N(C1-8alkyl)-CO-NR10R11; -CONR10R11 -N(R10)(R11);
-SO2N(R10)R11; R7 and R8 or R8 and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form.
2. A method according to claim 1 wherein at most one of R1, R2 or R3 is -CON(R10)R11; or -SO2N(R10)R11.
3. A method of claim 1 wherein the condition is a proliferative disease.
4. A method of claim 1 wherein a gene fusion containing ALK is inhibited.
5. Use of a compound of formula I
wherein X is =CR0- or =N-;
each of R0, R1, R2, R3 and R4 independently is hydrogen; hydroxy; C1-C8alkyl;
C2-C8alkenyl;
C3-C8cycloalkyl; C3-C8cycloalkyl-C1-C8alkyl; hydroxyC1-C8alkyl; C2-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkoxyC1-C8alkyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C1-C8alkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R1, R2 and R3, independently, is halogen; halo-C1-C8alkyl; C1-C8alkoxy; halo-C1-C8alkoxy; hydroxyC1-C8alkoxy; C1-C8alkoxyC1-C8alkoxy; aryl; arylC1-C8alkoxy;
heteroaryl; heteroaryl-C1-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-C8alkoxycarbonyl; C2-C8alkylcarbonyl; -N(C1-C8alkyl)C(O) C1-C8alkyl; -N(R10)R11;
-CON(R10)R11; -SO2N(R10)R11; or -C1-C4-alkylene-SO2N(R10)R11; wherein each of R10 and R11 independently is hydrogen; hydroxy; C1-C8alkyl; C1-C8alkenyl; C3-C8cycloalkyl;
C3-C8cycloalkyl-C1-C8alkyl; C1-C8alkoxyC1-C8alkyl; hydroxyC1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkyl; (C1-C8alkyl)-carbonyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C2-C8alkoxycarbonyl; or 5 to membered heterocyclic ring;
or R1 and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C1-C8alkyl; halo-C1-C8alkyl;
C1-C8alkenyl; C1-C8alkynyl; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl; C5-C10arylC1-C8alkyl;
each of R7, R8 and R9 is independently hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl;
halo-C1-C8alkyl; C1-C8alkoxy; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl;
arylC1-C8alkyl;
-Y-R12 wherein Y is a direct bond or O and R12 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxy; (C1-C8alkoxy)-carbonyl; -N(C1-8alkyl)-CO-NR10R11; -CONR10R11; -N(R10)(R11);
-SO2N(R10)R11; R7 and R8 or R8 and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form;
for the preparation of a medicament for the treatment of a hematological and neoplastic disease.
wherein X is =CR0- or =N-;
each of R0, R1, R2, R3 and R4 independently is hydrogen; hydroxy; C1-C8alkyl;
C2-C8alkenyl;
C3-C8cycloalkyl; C3-C8cycloalkyl-C1-C8alkyl; hydroxyC1-C8alkyl; C2-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkoxyC1-C8alkyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C1-C8alkoxycarbonyl;
or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;
or each of R1, R2 and R3, independently, is halogen; halo-C1-C8alkyl; C1-C8alkoxy; halo-C1-C8alkoxy; hydroxyC1-C8alkoxy; C1-C8alkoxyC1-C8alkoxy; aryl; arylC1-C8alkoxy;
heteroaryl; heteroaryl-C1-C4alkyl; 5 to 10 membered heterocyclic ring; nitro;
carboxy;
C2-C8alkoxycarbonyl; C2-C8alkylcarbonyl; -N(C1-C8alkyl)C(O) C1-C8alkyl; -N(R10)R11;
-CON(R10)R11; -SO2N(R10)R11; or -C1-C4-alkylene-SO2N(R10)R11; wherein each of R10 and R11 independently is hydrogen; hydroxy; C1-C8alkyl; C1-C8alkenyl; C3-C8cycloalkyl;
C3-C8cycloalkyl-C1-C8alkyl; C1-C8alkoxyC1-C8alkyl; hydroxyC1-C8alkoxyC1-C8alkyl;
hydroxyC1-C8alkyl; (C1-C8alkyl)-carbonyl; arylC1-C8alkyl which optionally may be substituted on the ring by hydroxy, C1-C8alkoxy, carboxy or C2-C8alkoxycarbonyl; or 5 to membered heterocyclic ring;
or R1 and R2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O
and S; or each of R5 and R6 independently is hydrogen; halogen; cyano; C1-C8alkyl; halo-C1-C8alkyl;
C1-C8alkenyl; C1-C8alkynyl; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl; C5-C10arylC1-C8alkyl;
each of R7, R8 and R9 is independently hydrogen; hydroxy; C1-C8alkyl; C2-C8alkenyl;
halo-C1-C8alkyl; C1-C8alkoxy; C3-C8cycloalkyl; C3-C8cycloalkylC1-C8alkyl;
arylC1-C8alkyl;
-Y-R12 wherein Y is a direct bond or O and R12 is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O
and S;
carboxy; (C1-C8alkoxy)-carbonyl; -N(C1-8alkyl)-CO-NR10R11; -CONR10R11; -N(R10)(R11);
-SO2N(R10)R11; R7 and R8 or R8 and R9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.
in free form or salt form;
for the preparation of a medicament for the treatment of a hematological and neoplastic disease.
6. A use according to claim 5 wherein at most one of R1, R2 or R3 is -CON(R10)R11; or -SO2N(R10)R11.
3. A use according to claim 5 wherein the condition is a proliferative disease.
4. A use according to claim 5 wherein a gene fusion containing ALK is inhibited.
3. A use according to claim 5 wherein the condition is a proliferative disease.
4. A use according to claim 5 wherein a gene fusion containing ALK is inhibited.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50437403P | 2003-09-18 | 2003-09-18 | |
US60/504,374 | 2003-09-18 | ||
PCT/EP2004/010466 WO2005026130A1 (en) | 2003-09-18 | 2004-09-17 | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2538413A1 true CA2538413A1 (en) | 2005-03-24 |
Family
ID=34312463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002538413A Abandoned CA2538413A1 (en) | 2003-09-18 | 2004-09-17 | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070105839A1 (en) |
EP (1) | EP1663992A1 (en) |
JP (1) | JP2007505858A (en) |
CN (1) | CN100584832C (en) |
AU (1) | AU2004272288B2 (en) |
BR (1) | BRPI0414544A (en) |
CA (1) | CA2538413A1 (en) |
MX (1) | MXPA06003054A (en) |
WO (1) | WO2005026130A1 (en) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
MXPA05001096A (en) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
SI1660458T1 (en) | 2003-08-15 | 2012-05-31 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
RU2006139258A (en) | 2004-04-08 | 2008-05-20 | Таргеджен, Инк. (US) | KINAZ BENZOTRIAZINE INHIBITORS |
AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
WO2006037117A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
DE602006010979D1 (en) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | PRODRUGS FROM 2,4-PYRIMIDIN DIAMIN COMPOUNDS AND THEIR USES |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
FR2888239B1 (en) * | 2005-07-11 | 2008-05-09 | Sanofi Aventis Sa | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS INHIBITORS OF IKK |
WO2007006926A2 (en) * | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
GB0517329D0 (en) * | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
EP1968950A4 (en) * | 2005-12-19 | 2010-04-28 | Genentech Inc | Pyrimidine kinase inhibitors |
KR101411695B1 (en) | 2006-02-17 | 2014-07-03 | 리겔 파마슈티칼스, 인크. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
CA2644356A1 (en) * | 2006-03-16 | 2007-09-27 | Novartis Ag | Heterocyclic organic compounds for the treatment of in particular melanoma |
MX2008012482A (en) | 2006-03-31 | 2008-10-10 | Abbott Lab | Indazole compounds. |
CA2982018C (en) * | 2006-04-14 | 2023-10-17 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
SI2450437T1 (en) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc. | Gene defects and mutant ALK kinase in human solid tumors |
CA2669111C (en) | 2006-10-23 | 2016-04-12 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
EP3012249A1 (en) | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
AU2007337088A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
AR065015A1 (en) | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | ANTRANILAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES FOR THE TREATMENT OF CANCER |
TW200840581A (en) * | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
TW200843776A (en) * | 2007-03-01 | 2008-11-16 | Supergen Inc | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
CN101686675A (en) * | 2007-03-20 | 2010-03-31 | 史密丝克莱恩比彻姆公司 | Compound |
RU2455994C2 (en) | 2007-04-16 | 2012-07-20 | Хатчисон Медифарма Энтерпрайзис Лимитед | Pyrimidine derivatives |
TWI389893B (en) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
WO2009010794A1 (en) * | 2007-07-19 | 2009-01-22 | Astrazeneca Ab | 2,4-diamino-pyrimidine derivatives |
WO2009032668A2 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
UY31929A (en) * | 2008-06-25 | 2010-01-05 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS |
WO2009158431A2 (en) * | 2008-06-25 | 2009-12-30 | Irm Llc | Compounds and compositions as kinase inhibitors |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (en) * | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
JP5697601B2 (en) * | 2008-12-01 | 2015-04-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 2,5-Diamino-substituted pyrido [4,3-D] pyrimidines as autotaxin inhibitors against cancer |
KR101705158B1 (en) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr inhibitors and methods of treating diseases |
EP2464633A1 (en) | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
JP2013523657A (en) * | 2010-03-26 | 2013-06-17 | グラクソ グループ リミテッド | Indazolyl-pyrimidine as a kinase inhibitor |
JP6022442B2 (en) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Male contraceptive compositions and methods of use |
BR112012029057A2 (en) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | leukemia compositions and treatment methods |
SI2902030T1 (en) | 2010-05-14 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
BR112012029647A2 (en) | 2010-05-21 | 2016-08-02 | Chemilia Ab | new pyrimidine derivatives |
KR20130099040A (en) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Besylate salt of a btk inhibitor |
NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
ES2635713T3 (en) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
JP5957003B2 (en) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Mutant selective EGFR inhibitor and use thereof |
RU2013147417A (en) | 2011-03-24 | 2015-04-27 | Кемилиа Аб | NEW PYRIMIDINE DERIVATIVES |
EA201391626A1 (en) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
JP2014532658A (en) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Methods for treating Breton tyrosine kinase diseases or disorders |
SG10201700799WA (en) | 2012-03-15 | 2017-02-27 | Celgene Avilomics Res Inc | Salts of an epidermal growth factor receptor kinase inhibitor |
ES2880109T3 (en) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
JP6469567B2 (en) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Compound for inhibiting cell proliferation of EGFR-activated cancer |
KR101446742B1 (en) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
BR112015022993B1 (en) | 2013-03-14 | 2021-12-14 | Sumitomo Dainippon Pharma Oncology, Inc. | JAK2 AND ALK2 INHIBITORS, PHARMACEUTICAL COMPOSITION INCLUDING SUCH INHIBITORS AND USE THEREOF |
WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104230960B (en) * | 2013-06-06 | 2017-02-15 | 山东轩竹医药科技有限公司 | Four-ring anaplastic lymphoma kinase inhibitor |
BR112016001457A2 (en) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
MX2016005980A (en) | 2013-11-08 | 2016-12-09 | Dana Farber Cancer Inst Inc | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors. |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN105940005A (en) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | Diazepane derivatives and uses thereof |
KR20160111520A (en) * | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | Dihydropteridinone derivatives and uses thereof |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
JP2017506666A (en) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス,インコーポレイテッド | Treatment of symptoms related to hyperinsulinemia |
RU2017104898A (en) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | DIHYDROPTERIDINONE DERIVATIVES AND THEIR APPLICATIONS |
CA2955074A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
EP3202765B1 (en) * | 2014-09-29 | 2020-03-25 | Hainan Xuanzhu Pharma Co., Ltd. | Polycyclic anaplastic lymphoma kinase inhibitor |
CR20170219A (en) | 2014-10-27 | 2017-08-14 | Tensha Therapeutics Inc | BROMODOMINUM INHIBITORS |
CN106146525B (en) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | Three and ring class anaplastic lymphoma kinase inhibitor |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CN106336398A (en) * | 2015-07-06 | 2017-01-18 | 杭州雷索药业有限公司 | 2-Saturated cyclosubstituted aniline protein kinase inhibitor |
CN106336382B (en) * | 2015-07-06 | 2022-04-05 | 杭州雷索药业有限公司 | 4-saturated cyclic substituted aniline protein kinase inhibitor |
MX2018003030A (en) | 2015-09-11 | 2018-04-11 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof. |
RU2750164C2 (en) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Cyanothienotriazolodiazepines and methods for their use |
MX2018006499A (en) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibtors and uses thereof. |
PL3442947T3 (en) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
NZ751713A (en) * | 2016-08-29 | 2022-07-01 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
KR101916773B1 (en) | 2017-07-04 | 2018-11-08 | 한국과학기술연구원 | Diaminopyrimidine derivatives for kinase inhibitors |
CA3079260A1 (en) * | 2017-10-17 | 2019-04-25 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof |
EP3697762A4 (en) * | 2017-10-18 | 2021-04-07 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof |
EP3773591A4 (en) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl kinase inhibitors and use of the same |
KR102063155B1 (en) * | 2018-04-11 | 2020-01-08 | 한국과학기술연구원 | multi-substituted pyrimidine derivatives showing excellent kinase inhibitory activities |
CN112236139A (en) | 2018-04-13 | 2021-01-15 | 大日本住友制药肿瘤公司 | PIM kinase inhibitors for the treatment of myeloproliferative tumors and cancer-associated fibrosis |
EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
CN111171017B (en) * | 2018-11-09 | 2021-12-24 | 天津大学 | Pyrimidine-based derivatives, their preparation and use |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN112469713B (en) * | 2019-06-21 | 2023-09-01 | 江苏豪森药业集团有限公司 | Aryl phosphorus oxide derivative inhibitor, preparation method and application thereof |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
CN110746402B (en) * | 2019-09-21 | 2021-01-15 | 温州医科大学 | 2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof |
CN110669038B (en) * | 2019-09-21 | 2020-10-30 | 温州医科大学 | Pyrimidine FGFR4V550LInhibitor, preparation method and application thereof |
CN111484484B (en) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 2, 4-diaryl aminopyrimidine derivative containing aromatic heterocycle and preparation and application thereof |
WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US7459455B2 (en) * | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
MXPA04008458A (en) * | 2002-03-01 | 2004-12-06 | Smithkline Beecham Corp | Diamino-pyrimidines and their use as angiogenesis inhibitors. |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP4634367B2 (en) * | 2003-02-20 | 2011-02-16 | スミスクライン ビーチャム コーポレーション | Pyrimidine compounds |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP4741491B2 (en) * | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-pyrimidinediamine compounds and uses as antiproliferative agents |
-
2004
- 2004-09-17 CA CA002538413A patent/CA2538413A1/en not_active Abandoned
- 2004-09-17 WO PCT/EP2004/010466 patent/WO2005026130A1/en active Application Filing
- 2004-09-17 US US10/571,733 patent/US20070105839A1/en not_active Abandoned
- 2004-09-17 JP JP2006526595A patent/JP2007505858A/en active Pending
- 2004-09-17 MX MXPA06003054A patent/MXPA06003054A/en not_active Application Discontinuation
- 2004-09-17 BR BRPI0414544-5A patent/BRPI0414544A/en not_active IP Right Cessation
- 2004-09-17 CN CN200480026942A patent/CN100584832C/en not_active Expired - Fee Related
- 2004-09-17 AU AU2004272288A patent/AU2004272288B2/en not_active Ceased
- 2004-09-17 EP EP04765358A patent/EP1663992A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN1852900A (en) | 2006-10-25 |
MXPA06003054A (en) | 2006-05-31 |
BRPI0414544A (en) | 2006-11-07 |
JP2007505858A (en) | 2007-03-15 |
AU2004272288A1 (en) | 2005-03-24 |
AU2004272288B2 (en) | 2008-11-13 |
US20070105839A1 (en) | 2007-05-10 |
CN100584832C (en) | 2010-01-27 |
WO2005026130A1 (en) | 2005-03-24 |
EP1663992A1 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2538413A1 (en) | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders | |
AU2003227070B2 (en) | Pyrimidine derivatives | |
AU2004272283B9 (en) | 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors | |
KR101238585B1 (en) | Compounds and compositions as protein kinase inhibitors | |
AU2005205118B2 (en) | Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors | |
JP2009544592A (en) | 2,4-Di (arylamino) -pyrimidine-5-carboxamide compounds as JAK kinase inhibitors | |
AU2005289136A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
CA2553243C (en) | Pyrrolo pyrimidine derivatives useful for treating proliferative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |